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Abstract
Objective
To compare the effectiveness and side effects of migraine prophylactic medications.
Design
We performed a network meta-analysis. Data were extracted independently in duplicate
and quality was assessed using both the JADAD and Cochrane Risk of Bias instruments.
Data were pooled and network meta-analysis performed using random effects models.
Data Sources
PUBMED, EMBASE, Cochrane Trial Registry, bibliography of retrieved articles through
18 May 2014.
Eligibility Criteria for Selecting Studies
We included randomized controlled trials of adults with migraine headaches of at least 4
weeks in duration.
Results
Placebo controlled trials included alpha blockers (n = 9), angiotensin converting enzyme
inhibitors (n = 3), angiotensin receptor blockers (n = 3), anticonvulsants (n = 32), beta-block-
ers (n = 39), calcium channel blockers (n = 12), flunarizine (n = 7), serotonin reuptake inhibi-
tors (n = 6), serotonin norepinephrine reuptake inhibitors (n = 1) serotonin agonists (n = 9)
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and tricyclic antidepressants (n = 11). In addition there were 53 trials comparing different
drugs. Drugs with at least 3 trials that were more effective than placebo for episodic
migraines included amitriptyline (SMD: -1.2, 95% CI: -1.7 to -0.82), -flunarizine (-1.1 head-
aches/month (ha/month), 95% CI: -1.6 to -0.67), fluoxetine (SMD: -0.57, 95% CI: -0.97 to
-0.17), metoprolol (-0.94 ha/month, 95% CI: -1.4 to -0.46), pizotifen (-0.43 ha/month, 95%
CI: -0.6 to -0.21), propranolol (-1.3 ha/month, 95% CI: -2.0 to -0.62), topiramate (-1.1 ha/
month, 95% CI: -1.9 to -0.73) and valproate (-1.5 ha/month, 95% CI: -2.1 to -0.8). Several
effective drugs with less than 3 trials included: 3 ace inhibitors (enalapril, lisinopril, capto-
pril), two angiotensin receptor blockers (candesartan, telmisartan), two anticonvulsants
(lamotrigine, levetiracetam), and several beta-blockers (atenolol, bisoprolol, timolol). Net-
work meta-analysis found amitriptyline to be better than several other medications including
candesartan, fluoxetine, propranolol, topiramate and valproate and no different than ateno-
lol, flunarizine, clomipramine or metoprolol.
Conclusion
Several drugs good evidence supporting efficacy. There is weak evidence supporting ami-
triptyline’s superiority over some drugs. Selection of prophylactic medication should be tai-
lored according to patient preferences, characteristics and side effect profiles.
Introduction
Migraine headaches are common, with a worldwide prevalence ranging between 8 and 18%
[1–7]. Migraines cause significant disability [8–11], even during periods between attacks [12],
and are responsible for $1 billion in medical costs and $16 billion in lost productivity per year
[13,14] in the US alone. The diagnostic criteria for migraine headaches have evolved over time.
Currently, the International Headache Society (IHS) diagnostic criteria for migraine includes
having at least 5 attacks that last 4–72 hours, that are unilateral, pulsating, moderate or severe
in intensity and aggravated by or cause avoidance of routine physical activity and are also
accompanied by nausea and/or vomiting, photophobia or phonophobia [15]. IHS further clas-
sifies migraine as with or without an aura and as episodic or chronic. Chronic migraine is
defined as more than 15 migraine headaches per month for more than 3 months. Chronic
migraines result in significantly greater disability than episodic migraines[16].
Treatment of headaches can be either abortive or prophylactic. Abortive treatment provides
symptom relief for the acute headache [17,18], while prophylactic treatment aims to reduce the
frequency or severity of headaches over time. We focus on prophylactic migraine headache
treatment in this manuscript. There are a large number of prophylactic treatment options
available; common ones include alpha antagonists, anti-convulsants [19], beta-blockers [20],
botulinum-A [21], calcium channel blockers [22], serotonin agonists[23], serotonin reuptake
inhibitors (SSRIs) [24] and tricyclic antidepressants (TCAs) [25]. Two emerging prophylactic
candidates are angiotensin converting enzymes (ACE) and angiotensin receptor antagonists
(ARB). Unfortunately nearly half of males and a third of females who are candidates for pro-
phylactic therapy do not receive it [26]. Selection of prophylactic treatment is tailored on indi-
vidual patient characteristics, costs and side effects of the available options. However, for
patients and their providers, the decision about which prophylactic regimen to use is hampered
by the lack of head to head trials comparing the different classes of medications. In addition,
Meta-Analysis of Prophylactic Treatment of Migraine Headaches
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previous systematic reviews have focused on single classes of drugs. Two recent systematic
reviews that looked more broadly at different drug options have been published. One only
included studies since 1999 and did not pool any results, providing qualitative statements
about relative treatment effectiveness [27]. Another review analyzed focused only on dichoto-
mous outcomes among patients with episodic migraines and found no difference in likelihood
of experiencing at least 50% improvement in headaches between different classes of oral medi-
cations [28]. Previous systematic reviews have also had methodological problems. Some com-
bine outcomes from the end of the study, regardless of study duration. This inappropriately
combines study results at markedly different time points. This also tends to overstate the
strength of the evidence by making it appear that there are more studies contributing data to
the results and produces inappropriately narrow confidence intervals. We conducted a meta-
analysis asking what is the comparative effectiveness and side effects of the prophylactic treat-
ment of migraine headaches in adults using oral pharmacological medications.
Materials and Methods
This report closely adheres to the PRISMA guidelines for conducting a systematic review [29].
We searched MEDLINE, EMBASE, the bibliographies of all retrieved articles, published sys-
tematic reviews and the Cochrane Database of Clinical Trials for each of the classes of medica-
tions (Table 1) through 7 November 2014. The search was conducted independently in
duplicate. We included published, randomized clinical trials that evaluated efficacy in reducing
the frequency or severity of migraine headaches that were at least 4 weeks in duration among
adults. These comparisons could be between active treatment with placebo controls or compar-
ative trials comparing two or more active treatments. We did not include unpublished data as
there is no systematic means of searching for it. Because the classification of headache has
changed over time [30,31], two authors independently reviewed each included article's head-
ache definition and, where possible, classified it according to the 3rd edition of the Interna-
tional Headache Society (IHS) criteria (ICDH-III) and included only those that could
reasonably be defined based on these diagnostic criteria [15]. For headache trials before 2004,
we classified trials as focusing on episodic or chronic migraine based on the number of head-
aches experienced by participants at baseline.
Two authors independently abstracted data. Because measures of headache outcomes var-
ied, a priori we followed International Headache Society outcome recommendations by priori-
tizing abstraction and analysis in this order: 1) headache frequency, 2) a headache index that
included frequency, 3) severity or 4) duration [32]. Headache frequency was standardized to
number of headaches per month. Whenever possible, we pooled frequency as the number of
headaches/month. When not possible, we pooled standardized mean differences between stud-
ies, a measure also known as an effect size. By convention, effect sizes greater than 0.8 are con-
sidered to be large effect sizes, 0.5–0.8 moderate and 0.2–0.5 small [33]. When missing,
variances were calculated from reported mean, sample size and p values [34]; for one non-pla-
cebo comparison trial [35] variance was imputed based on sample size and the reported effect
size (r2 = 0.76) When not explicitly reported, to verify we were using the proper variance, we
tested the abstracted data for each article to ensure that the p value reported in the article
matched our analysis. This helped insure that standard errors weren’t abstracted as standard
deviations, a common error in systematic reviews [36]. In addition, because of reports on the
potential for misleading data [37,38], we only accepted data that was unadjusted and that was
either based on a true intention to treat analysis or based on the subjects remaining in the trial.
We rejected any “modified intention to treat” analyses or analyses subject to other adjustments.
We assessed article quality independently and in duplicate, using both component and scales
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approaches using the Cochrane Risk of Bias Tool [39] and the Jadad scale [40] with good inter-
rater agreement (Cochrane ICC: 0.83; Jadad kappa: 0.85). Disagreements were resolved by
consensus.
For studies with more than one arm or using a cross-over design, we followed the recom-
mendations of the Cochrane collaboration by pooling the arms into a single arm (if the study
Table 1. Search Strategies.
Search Purpose Search Strategy
Headaches (headache OR headache disorders OR migrain* OR headache* OR
cephalgi* OR cephalalgi* OR tension*)
Randomized controlled trials (randomized controlled trial [pt] OR controlled clinical trial [pt] OR
randomized controlled trials [mh] OR random allocation [mh] OR double-
blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR
clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw]
OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR
(placebos [mh] OR placebo* [tw] OR random* [tw] OR research design
[mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR
follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR
prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT humans
[mh])
Alpha blockers (“Adrenergic alpha-Antagonists”[MeSH Terms]or clonidine OR tizanidine)
Angiotension converting
enzyme inhibitor
“Angiotenin-Converting Enzyme Inhibitors” [mh] OR benzapril OR
captopril OR enalapril OR lisinopril OR moexipril OR perindopril OR
quinapril OR ramipril OR trandolapril
Angiotension receptor blockers “Angiotensin Receptor Antagonists” [mh] OR losartan OR irbesartan OR
olmesartan OR candesartan OR valsartan OR telmisartan
Anticonvulsants ((anticonvulsants [mh] OR (anticonvulsant* OR antiepileptic* OR
acetazolamide OR carbamazepine OR chlormethiazole OR clobazam
OR clorazepate OR divalproex OR ethosuximide OR felbamate OR
fosphenytoin OR gabapentin OR lamotrigine OR levetiracetam OR
mephobarbital OR methsuximide OR midazolam OR oxcarbazepine OR
paraldehyde OR pentobarbital OR phenobarbital OR phenytoin OR
primidone OR valproate OR tiagabine OR topiramate OR valproic* OR
vigabatrin OR zonisamide)
Beta-blocker adrenergic beta receptor blockaders [mh] OR (alprenolol OR bucindolol
OR carteolol OR carvedilol OR labetalol OR nadolol OR penbutolol OR
pindolol OR propranolol OR Sotalol OR timolol OR acebutolol OR
atenolol OR betaxolol OR bisoprolol OR celiprolol OR esmolol OR
metoprolol OR nebivolol)
Calcium channel blocker (calcium channel blockers/therapeutic use"[mh] OR (amlodipine OR
aranidipine OR azelnidipine OR barnidipine OR benidipine OR bepridil
OR cilnidipine OR clevidipine OR diltiazem OR efonidipine OR felodipine
OR fendiline OR ﬂunarizine OR ﬂuspirilene OR gallopamil OR isradipine
OR lacidipine OR lercanidipine OR manidipine OR mibefradil OR
nicardipine OR nifedipine OR nilvadipine OR nimodipine OR nisoldipine
OR nitrendipine OR pranidipine OR verapamil))
Selective serotonin reuptake
inhibitor
serotonin Uptake Inhibitors/therapeutic use [MH] OR (citalopram OR
dapoxetine OR escitalopram OR ﬂuoxetine OR ﬂuvoxamine OR indalpine
OR paroxetine OR sertraline OR vilazodone OR zimelidine OR
venlafaxine OR desvenlafaxine OR duloxetine OR milnacipran OR
levomilnacipran OR sibutramine OR bicifadine)
Serotonin agonist (Pizotifen) Pizotyline [mh] OR pizotifen OR sandomigran
Tricyclic antidepressant antidepressive agents, tricyclic OR antidepressive$ OR tricyclic$ OR
amitriptyline OR amoxapine OR clomipramine OR desipramine OR
dibenzepin OR dothiepin OR doxepin OR imipramine OR lofepramine
OR nortriptyline OR opipramol OR protriptyline OR trimipramine
* (is the symbol for wild-card in MEDLINE)
doi:10.1371/journal.pone.0130733.t001
Meta-Analysis of Prophylactic Treatment of Migraine Headaches
PLOS ONE | DOI:10.1371/journal.pone.0130733 July 14, 2015 4 / 60
reported no differences between arms) or by reducing the sample sizes for cross-over trials by
50% [41]. We abstracted data from each trial at the following time points: baseline, 4, 8, 12, 24,
30 and 36 weeks using the DerSimonian and Laird random effects model [42]. Because of con-
troversy about the accuracy of reporting of off-label use of one of gabapentin [37,38], we relied
on data in McCrory’s reanalysis of misleading data presented in one of the studies [43] based
on drug company trial data.
The main focus of our analysis is between active treatment and placebo controls. We also
included data from comparative effectiveness trials. In addition to direct comparisons between
drugs, we also conducted a network meta-analysis [44–47]. In brief, network meta-analysis
asks if one drug has a pooled efficacy compared to placebo of X and another drug has a pooled
efficacy compared to placebo of Y, are X and Y statistically different? We only included drugs
with at least 2 clinical trials and at least 8 weeks in duration, adjusting for duration and for cor-
relation between outcomes reported from the same trial. Because these studies did not always
report their outcomes in frequency of headaches, the network meta-analysis was done using
standardized mean differences (SMD) rather than weighted mean differences.
Heterogeneity was assessed visually using Galbraith plots [48], and I-square [49].We
assessed for small study effects (publication bias) using the methods of Peters [50] for dichoto-
mous outcomes and Eggers [51] for continuous ones. We explored the potential source of het-
erogeneity using stratified analysis and random-effects meta-regression [52]. These analyses
included assessment of the impact of quality, study duration, percentage women, losses to fol-
low-up, and drug dose. All analyses were done using STATA (v 13.1, College Station TX).
There was no external funding for this study.
Results
Individual searches yielded 4789 unique articles: 138 ACE, 195 alpha blockers, 109 ARB, 1391
anticonvulsants, 654 beta blockers, 711 calcium channel blockers, 279 serotonin agonists, 363
SSRI and 876 TCA publications. Application of inclusion criteria (Fig 1) resulted in selecting
179 randomized clinical trials. These included the following placebo controlled trials: 9 alpha
blockers [53–61], 3 ACE trials [62–64] 3 ARB [65–67], 33 anticonvulsants [43,68–99], 39 beta-
blockers [66,73,100–136], 12 calcium channel blocker [106,137–147], 7 flunarizine [148–154],
6 SSRI [155–160], 1 SNRI [161], 9 serotonin agonists [162–170] and 9 TCA [118,136,171–177]
trials. Fifteen of these placebo-controlled trials included more than one active treatment
[66,74,106,116,118,131,136,141,163,167,169,170,175,178,179]. In addition, we also include 53
non-placebo controlled comparative effectiveness trials [178–230].
Placebo Comparisons
Table 2 provides study characteristics of trials investigating prophylactic treatment of episodic
migraines (< 15 headaches/month), Table 3 provides details about studies of chronic migraine
(>15 headaches/month) and chronic daily headache. There were a total of 15,493 participants
in the placebo controlled trials. Studies averaged 112 participants, ranging from 9 to 783. The
average patient was 39.2 years old and 78% of subjects were women. Included studies averaged
12 weeks in duration (range 4–82) and had a mean dropout rate of 24%. Thirty nine trials used
the 1962 Ad Hoc Committee criteria, seven used the 1969 World Federation of Neurology cri-
teria, forty seven studies used the 1988 International Headache Society criteria, and sixteen the
2004 IHS criteria. Among included trials, most (n = 120) studied episodic migraine headaches
with subjects averaging 5.6 headaches per month (range 1.2–11.7). Ten studies focused on sub-
jects with chronic migraine with an average of 18.6 (range 12–24) headaches a month. Six stud-
ied chronic daily headaches; the majority of participants (73%) had chronic migraine. Ninety
Meta-Analysis of Prophylactic Treatment of Migraine Headaches
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Fig 1. PRISMA Flowchart of study selection.
doi:10.1371/journal.pone.0130733.g001
Meta-Analysis of Prophylactic Treatment of Migraine Headaches
PLOS ONE | DOI:10.1371/journal.pone.0130733 July 14, 2015 6 / 60
Table 2. Study characteristics of included randomized trials of treatment of episodic (<15 headaches/month) migraine headaches.
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Drugs (mg) Headache
Measure
Study
design
(washout)
Duration,
weeks
Sample
size
Dropouts Age Female
ALPHA BLOCKER
Adam [53],
1978, UK
Episodic ns Clonidine (0.15) Frequency Crossover (0) 24 96 27% 37.5 84%
Boison [54],
1978, Denmark
Episodic ns Clonidine (0.1) Frequency Crossover (0) 8 71 31% ns ns
Bredfeldt[55],
1989, USA
Episodic ns Clonidine (0.2) Frequency Crossover 6 43 30% ns 80%
Lynggaard [56],
1975, Denmark
Episodic ns Clonidine (0.1) Frequency Crossover (1) 12 37 26% 34.1 95%
Mondrup[57],
1977, Denmark
Episodic ns Clonidine (0.1) Frequency Crossover (4) 12 32 34% 35 76%
Ryan [58], 1975,
USA
Episodic ns Clonidine (0.15) Frequency Crossover
(2 days)
8 133 ns 41 78%
Shafar [60],
1972, UK
Episodic 8.4 Clonidine (0.1) Frequency Crossover 8 65 23% 47.4 84%
Stensrud, 1976,
Norway
Episodic 5.8 Clonidine (0.15) Frequency Crossover (0) 7 29 7% 43.3 83%
ANGIOTENSIN ENZYME CONVERTING INHIBITORS
Paterna [62]
1992, Italy
Episodic Captopril (75) Headache
Index
Crossover 16 20 23% 37 81%
Schrader [63]
2001,Norway
Episodic 2.3 Lisinopril (20) Frequency Parallel 12 30 5% 41 81%
Sonbolestan
[64], 2013, Iran
Episodic 11.3 Enalapril (10) Frequency Parallel 8 34 0% 34.4 825
ANGIOTENSIN RECEPTOR BLOCKER
Diener[65] 2009,
Germany
Episodic 6.9 Telmisartan (80) Frequency Parallel 12 95 5% 47 85%
Stovner[66],
2013, Norway
Episodic 4.8 Candesartan (16),
Propranolol (160)
Frequency Crossover 12 61 15% 37 82%
Tronvik [67]
(2003) Norway
Episodic 5.7 Candesartan (16) Frequency Parallel 12 57 5% 43.2 79%
ANTICONVULSANTS
Brandes [69],
2004, Canada/
USA
Episodic 5.7 Topiramate,
(50,100,200)
Frequency Parallel 26 483 46% 38.9 87%
Cady [70], 2009,
USA
Episodic 4.4 Carisbamate
(100,300,600)
Frequency Parallel 14 318 30% 41.3 85%
de Tommaso
[71], 2007, Italy
Episodic 10.9 Topiramate (100),
Levitracetam (1000)
Frequency Parallel 8 45 16% 37.8 78%
Di’ Trapani [72],
2000, Italy
Episodic 5.2 Gabapentin (1200) Frequency Parallel 12 63 0% ns 52%
Diener [73],
2004 Europe
Episodic 5.1 Topiramate (100, 200)
Propranolol (160)
Frequency Parallel 20 568 37% 40.8 80%
Edwards [75],
2003, USA
Episodic 4.5 Topiramate (200) Frequency Parallel 4 70 0% 41.4 97%
Freitag [76],
2002,USA
Episodic 4.2 Divalproex (1000) Frequency Parallel 12 237 15% 40.5 79%
Ghose[77],
2002, New
Zealand
Episodic
(74%)
Chronic
(26%)
7.6 Vigabatrin (2000) Frequency Crossover (4) 12 23 17% 43.6 74%
(Continued)
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Table 2. (Continued)
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Drugs (mg) Headache
Measure
Study
design
(washout)
Duration,
weeks
Sample
size
Dropouts Age Female
Gupta [78],
2007, India
Episodic 7.0 Topiramate (50),
Lamotrigene (50)
Frequency Crossover () 4 60 7% 30 78%
Hering
[79],1992. Israel
Episodic 7.7 Valproate (800) Frequency Crossover (0) 8 32 9% 34 79%
Jensen
[80],1994,
Denmark
Episodic 6.6 Valproate (1500) Frequency Crossover (4) 12 43 21% 46 86%
Klapper
[81],1997, USA
Episodic 5.0 Divalproex
(500,100,1500)
Frequency Parallel 12 176 22% 40.8 89%
Lipton [82],
2011, USA
Episodic 11.7 Topiramate (100) Frequency Parallel 26 385 14% 40.3 89%
Mathew [83],
1995, USA
Episodic 6.2 Valproate (750) Frequency Parallel 12 107 16% 45.6 78%
Mathew [43],
2001,USA
Episodic 4.9 Gabapentin (2400) Frequency Parallel 12 143 39% 40 83%
Rompel [85],
1970, S Africa
Episodic 3.0 Carbamazepin (ns) Frequency Crossover () 6 48 2% 60 69%
Silberstein
[87],2004, USA
Episodic 5.5 Topiramate
(50,100,200)
Frequency Parallel 24 487 46% 40.4 89%
Silberstein [88],
2006, USA
Episodic 4.9 Topiramate (200) Frequency Parallel 20 211 27% 40.8 86%
Silberstein [90],
2008, USA
Episodic 3–9 Oxcarbazepine(1200) Frequency Parallel 15 170 26% 40.5 85%
Silberstein [91],
2013, USA
Episodic 9.2 Gabapentin
(1200,1800,2400,3000)
Frequency Parallel 20 263 29% 39.3–
40.6
83%
Steiner
[94],1997, UK
Episodic 4.1 Lamotrigine (200) Frequency Parallel 12 77 31% 37.2 82%
Stensrud
[95],1979,
Norway
Episodic 6.3 Clonazepam (1) Frequency Crossover () 4 38 11% ns 71%
Storey
[96],2001, USA
Episodic 4.7 Topiramate (200) Frequency Parallel 16 40 13% 38.3 98%
Vahedi
[97],2002,
France
Episodic 5.0 Acetazolamide (500) Frequency Parallel 12 53 34% 39.2 75%
Verma[98],
2013, India
Episodic 5.7 Levetiracetam Frequency Parallel 12 65 20% 31.1 73%
Beta Blockers
Ahuja[100],
1985, India
Episodic 7.2 Propranolol (120) Frequency Crossover 8 26 ns ns 46%
Al-Qassab [101],
1993, UK
Episodic 4 Propranolol (80, 160) Frequency Crossover 8 45 33% 36 80%
Andersson [102],
1983, Denmark
Episodic 4.9 Metoprolol (200) Frequency Parallel 8 71 13% 39.6 85%
Borgesen [103],
1974, Denmark
Episodic 1.8 Propranolol (120) Frequency Crossover 12 45 33% 37.6 83%
Briggs [104],
1979, UK
Episodic 6.9 Tomolol (20) Frequency Crossover 6 24 4% ns 71%
Dahlof [105],
1987, Sweden
Episodic 4.3 Propranolol (120) Frequency Crossover 4 29 0% ns 83%
Diener [106],
1996, Germany
Episodic 4 Propranolol (120)
Clyclandelate (1200)
Duration Parallel 20 214 19% 39 78%
(Continued)
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Table 2. (Continued)
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Drugs (mg) Headache
Measure
Study
design
(washout)
Duration,
weeks
Sample
size
Dropouts Age Female
Diener [73],
2004, Germany
Episodic 5.1 Propranolol (160) Frequency Parallel 20 568 37% 40.8 80%
Ekbom [107],
1972, Sweden
Episodic 11.7 Pindolol (7.5, 15) Frequency Parallel 4 30 13% 33.7 87%
Ekbom [108],
1975, Sweden
Episodic 2.2 Alprenolol (400) Frequency Parallel 6 33 15% 41.3 82%
Ekbom
[109],1977,
Sweden
Episodic >3 Oxprenolol Headache
Index
Crossover (1) 12 34 46% 41.8 89%
Forssman [110],
1976, Sweden
Episodic 6.9 Propranolol (240) Frequency Crossover 12 40 20% 37.4 97%
Forssman [111],
1983, Sweden
Episodic >3 Atenolol (100) Frequency Crossover 12 24 17% 40 80%
Freitag [112],
1984, USA
Unclear ns Nadolol (160, 240) Frequency Parallel ns 32 ns ns 81%
Holroyd [113],
2010, USA
Episodic 5.4 Propranolol (180) Frequency Parallel 64 232
(35%)
35% 38.2 78%
Johannsson
[114], 1987,
Sweden
Episodic >2 Atenolol (100) Frequency Crossover 12 Ns 14% 43 70%
Johnson [115],
1986, New
Zealand
Episodic 5 Propranolol (240) Frequency Crossover 12 29 41% 42 69%
Kangasniemi
[116], 1987,
Norway
Episodic 4.3 Metoprolol (200) Frequency Crossover (4) 8 74 1% 37.5 79%
Langohr
[175],1985,
Germany
Episodic Propranolol ()
Clomipramine (
Frequency Crossover (4) 12 36 43% 44 74%
Malvea [117],
1973, USA
Episodic >4 Propranolol (?) Headache
Index
Crossover 6 31 6% ns 87%
Mathew [118],
1981, USA
Unclear ns Propranolol (75)
Amitriptyline (75)
Headache
Index
Parallel 24 554 22% 38 95%
Mikkelsen [119],
1986, Denmark
Episodic >3 Propranolol (120) Frequency Crossover (0) 12 39 21% ns 84%
Nadelmann
[120], 1986,
USA
Unclear ns Propranolol (240) Headache
Index
Crossover (0) 6 64 36% ns 86%
Nanda [121],
1977, Scotland
Episodic 4.8 Acebutolol (800) Frequency Crossover (4) 12 43 24% ns 74%
Pita [123], 1977,
Spain
Episodic 5.5 Propranolol (160) Headache
Index
Crossover (0) 8 9 11% 32 78%
Pradalier [124],
1989, France
Episodic 6.1 Propranolol (160) Frequency Parallel 12 74 25% 37.5 76%
Sargent [125],
1985, USA
Episodic >2 Propranolol (120) Frequency Parallel 16 161 13% 30 79%
Sjaastad [126],
1972, Norway
Episodic 7.5 Pindolol (7.5) Frequency Crossover (3) 4 24 17% 35.3 75%
Standnes [127],
1982, Norway,
Episodic 6.7 Propranolol (160)
Timolol (20)
Frequency Crossover 0 25 28% ns 80%
Steiner [128],
1988, UK
Episodic 4 Metoprolol (100) Frequency Parallel 8 59 19% 37.6 76%
(Continued)
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Table 2. (Continued)
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Drugs (mg) Headache
Measure
Study
design
(washout)
Duration,
weeks
Sample
size
Dropouts Age Female
Stellar [129],
1984, USA
Episodic 6.8 Timolol (30) Frequency Crossover 6 107 8% 43 72%
Stensrud [130],
1976, Norway
Episodic 6.1 Propranolol (160)
Inderal (160)
Headache
Index
Crossover (1) 4 20 5% ns 70%
Stensrud [131],
1980, Norway
Episodic
(n = 21)
<15>15 Atenolol (100)
Propranolol (160)
Frequency Crossover (1) 6 21 20% ns 69%
Tfelt-Hansen
[132], 1984,
Scandinavia
Episodic 6.0 Timolol (20)Propranolol
(160)
Frequency Crossover (2) 10 96 10% 39.5 74.5%
Van de Ven
[133], 1997,
Denmark
Episodic 5.5 Bisoprolol (10) Frequency Parallel 8 226 14% 38.7 82%
Weber [134],
1972, USA
Unclear ns Propranolol (80) Headache
Index
Crossover (0) 12 25 24% 40.5 52%
Wideroe [135],
1974, Norway
Episodic 3 Propranolol (160) Headache
Index
Crossover (0) 12 30 13% 38 87%
Zeigler [136],
1987, USA
Episodic 2–12 Propranolol (240) Headache
Index
Crossover (4) 4 30 ns 38 73%
Calcium Channel Blockers
Nimodipine
European
Migraine (with
aura) Trial [137],
1989, EU
Episodic 3.3 Nimodipine (120) Frequency Parallel 12 89 19% 33.8 79%
Nimodipine
European
Migraine
(Without aura)
trial (1989) [138],
EU
Episodic 4.4 Nimodipine (120) Frequency Parallel 12 192 16% 38.1 78%
Ansell [139],
1988, UK
Episodic >2 Nimodipine (120) Headache
Index
Parallel 12 68 16% ns 71%
Gelmers [140],
1983,
Netherlands
Episodic 9.1 Nimodipine (120) Headache
Index
Parallel 12 60 17% 30 62%
Havanka-
Kanniainen
[141], 1985,
Finland
Episodic 7.9 Nimodipine (120) Frequency Crossover (0) 8 33 12% 33 85%
Leandri [142],
1990, Italy
Episodic 4.3 Nicardipine (40) Frequency Crossover
(ns)
8 35 15% ns ns
Markley [143],
1984, USA
Episodic 3.4 Verapamil (240) Frequency Crossover
(ns)
8 20 30% 33 86%
McArthur [144],
1989, USA
Episodic 2.3 Nifedipine (90) Frequency Crossover (1) 12 24 42% ns ns
Shukla [145],
1995, UK
Episodic 10.4 Nifedipine (15) Frequency Crossover
(ns)
6 36 22% 22.8 50%
Solomon [146],
1983, USA
Episodic 6.7 Verapamil (320) Frequency Crossover
(ns)
6 12 52% 38 78%
Stewart [147],
1988, Canada
Episodic 6.3 Nimodipine (120) Frequency Parallel 8 37 19% ns ns
Flunarizine
(Continued)
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Table 2. (Continued)
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Drugs (mg) Headache
Measure
Study
design
(washout)
Duration,
weeks
Sample
size
Dropouts Age Female
Diamond [148],
1992, USA
Episodic 4.3 Flunarizine (10) Frequency Parallel 20 143 8% 34.8 74%
Frenken [149],
1984,
Netherlands
Episodic 3.6 Flunarizine (10) Frequency Parallel 12 35 0% NS 83%
Louis [150],
1981, Belgium
Episodic 1.2 Flunarizine (10) Frequency Parallel 12 58 0% 29 50%
Mendenopoulos
[151], 1985,
Greece
Episodic 4 Flunarizine (10) Headache
Index
Parallel 12 20 0% 44 80%
Pini [152], 1986,
Italy
Episodic 9.9 Flunarizine (20) Headache
Index
Parallel 4 18 0% 40.2 83%
Sorensen [153],
1986, Denmark
Episodic 3 Flunarizine (10) Frequency Crossover (4) 16 29 7% 40 79%
Thomas [154],
1991, India
Episodic 6.7 Flunarizine (10) Headache
Index
Crossover (2) 12 29 48% 30.5 87%
Selective Serotonin Reuptake Inhibitor
Adly [155], 1993,
USA.
Episodic >4 Fluoxetine (40) Headache
Index
Parallel 10 32 44% 37.5 83%
d'Amato [156],
1999, Italy.
Episodic 1–4 Fluoxetine (20) Headache
Index
Parallel 20 52 0% 37.6 63%
Landy [157],
1998, USA.
Episodic >2 Sertraline (50) Headache
Index
Parallel 8 27 41% 36 93%
Steiner [159],
1998, UK.
Episodic 3.9 s-Fluoxetine (40) Frequency Parallel 12 53 32% 37 75%
Zeeberg [160],
1981, Sweden
Episodic 3.5 Femoxitine (300) Headache
Index
Parallel 12 59 ns ns ns
Serotonin Norepinephrine Reuptake Inhibitor
Ozyalcin [161],
2004, Turkey
Episodic 2.3 Venlafaxine (75, 150) Frequency Parallel 8 60 17% 36.5 83%
Serotonin Agonist
Arthur [162],
1971, New
Zealand
Episodic 8.1 Pizotifen (3.0) Frequency Crossover
(ns)
4 63 17% ns ns
Bellavance
[163], 1990,
Canada
Episodic 6.7 Pizotifen (1.5) Frequency Parallel 12 176 14% 32.5 79%
Carroll [164],
1975, UK
Episodic >3 Pizotifen (3.0) Headache
Index
Crossover (2) 4 27 48% ns ns
Cleland [165],
1997, UK
Episodic 3.4 Pizotifen (2.0) Frequency Crossover
(ns)
12 130 32% 40.5 63%
Hughes [166],
1971, UK
Episodic 9.1 Pizotifen (0.5) Frequency Crossover
(ns)
12 26 0% ns 81%
Kangasniemi
[167], 1979,
Finland
Episodic 4.3 Pizotifen (1.5) Frequency Crossover (0) 7 50 22% 36 80%
Lance, 1968 Pizotifen
Lawrence [168],
1977, UK
Episodic >4 Pizotifen (1.5) Headache
Index
Parallel 12 36 14% ns 79%
Osterman [169],
1977, Sweden
Episodic 5.1 Pizotifen (0.5) Frequency Crossover (2) 8 30 10% 37 70%
Ryan [170],
1968, USA
Episodic 8.9 Pizotifen (4) Frequency Crossover
(ns)
4 62 ns ns ns
(Continued)
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trials (57%) used a parallel-group design, while sixty-six used a crossover design. There were 23
countries contributing studies. Fifty-one trials (46%) were sponsored by industry. Most studies
(82%) used frequency as their outcome measure, nineteen (13.7%) used a headache index, two
used headache duration and three headache intensity.
Overall, the studies varied in quality. Quality ratings for placebo controlled trials are given
in Table 4. By Jadad criteria, 34% of studies had scores 3.0, suggesting low quality, 39% had
scores between 3 and 5 consistent with modest quality and only 37% had scores 5 suggesting
high quality. Only 36% used an intention to treat analysis, 27% assessed compliance, 26% had
concealed allocation, and 51% had adequate blinding. There was no difference in the overall
effect sizes for placebo controlled trials using Jadad criteria as a scale (p = 0.44) or when coded
as high, modest or low quality (p = 0.37), or when assessed by most of the specific Jadad or
Cochrane Risk of Bias quality characteristics (compliance p = 0.59; blinding p = 0.36; adequacy
of blinding p = 0.50, industry sponsorship p = 0.52; incomplete outcome reporting p = 0.96,
reporting of withdrawals p = 0.24). However, trials which had inadequate concealed allocation
had significantly (p = 0.02) higher reported effects (SMD: -0.52, 95% CI: -0.63 to -0.41) than
those who had concealed allocation (SMD: -0.26, 95% CI: -0.34 to 0.17).
Alpha-blockers. There were 9 trials comparing alpha blockers to placebo with a total of
4590 participants who averaged 39.3 (range 12–76) years in age with 84% women (Table 2). All
of the studies measured headache frequency. Eight of these trials focused on episodic migraine
headaches; all studied clonidine. One trial focused on chronic migraines using tizanidine. The
average rate of withdrawals was 32%. Studies averaged 11 weeks (range 4–82) with a mean of
71.3 participants (range 11–67). At no time point was clonidine more effective than placebo for
episodic migraines (Table 5, Fig 2) and tizanidine was no more effective than placebo for
chronic migraine headaches (Table 6). None of these trials reported on the likelihood of a 50%
reduction in headaches.
Table 2. (Continued)
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Drugs (mg) Headache
Measure
Study
design
(washout)
Duration,
weeks
Sample
size
Dropouts Age Female
Tricyclic Antidepressants
Couch [241],
1976, USA
Episodic 6.9 Amitriptyline (100) Headache
Index
Parallel 4 73 36% NS 64%
Couch [171],
1979
Episodic 6.9 Amitriptyline (100) Frequency Parallel 8 162 38% NS 85%
Couch [172],
2011, USA
Episodic 7.6 Amitriptyline (100) Frequency Parallel 16 391 51% 34.9 81%
Gomersall [173],
1973, UK
Episodic 2.7 Amitriptyline (60) Frequency Crossover (0) 26 20 20% 42 75%
Jacobs [174],
1972, UK
Episodic 3.3 Opipramol (75) Frequency Parallel 12 27 43% 42 78%
Langohr [175],
1985, Germany
Episodic >4 Clomipramine (100) Frequency Crossover (4) 4 36 43% 44 67%
Mathew [118],
1981, USA
Unclear Unclear Amitriptyline (75) Headache
Index
Parallel 24 554 22% 38 95%
Noone [177],
1980, UK
Episodic 6 Clomipramine (30) Frequency Crossover 4 10 50% Ns 70%
Ziegler [136],
1987, USA
Episodic 2–12 Amitriptyline (100) Headache
Index
Crossover (1) 8 30 0% 38 73%
doi:10.1371/journal.pone.0130733.t002
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Angiotensin Converting Enzyme Inhibitors (ACE)/ Angiotensin Receptor Blockers
(ARB). There were three ACE (captopril, enalapril, lisinopril) and three ARB (candesartan
x2, telmisartan) placebo-controlled trials, all focusing on episodic migraines (Table 2). The
ACE studies were 8, 12 and 16 weeks in duration with 120 participants who averaged 7.3 head-
aches per month. All three ARB studies were 12 weeks in duration with a total of 231 partici-
pants, averaging 6.5 headaches/month. One of the ACE trials suggested no benefit at 4 or 8
weeks (enalapril), another found benefit at 12 weeks (lisinopril) and a third benefit at 16 weeks
(captopril, Table 5, Fig 3); none of the trials reported outcomes at a common time-point. At
twelve weeks, ARBs were better than placebo in reducing the frequency of headaches (Table 5,
Fig 3). The likelihood of experiencing at least 50% improvement was not reported in all clinical
trials. One of the ACE trials (captopril) was more likely than placebo to achieve at least a 50%
reduction in headache frequency (Table 7). This was not found in the trial studying lisinopril
or for two of the ARB trials.
Anticonvulsants. There were 32 trials comparing anticonvulsants to placebo with a total
of 8529 participants who averaged 41 years (range 12–76) in age; 81% of participants were
women (Table 2). Twenty-seven of these trials focused on episodic migraine headaches
(Table 2), five evaluated chronic migraine and four chronic daily headaches (Table 3). The
Table 3. Study characteristics of included randomized trials of treatment of chronic (15 headaches/month) migraine headaches.
Alpha Blocker
Saper [59], 2002,
USA
Chronic ns Tizanidine (24) Headache
Index
Parallel 12 136 32% 40 79%
Anticonvulsant
Diener [74], 2007,
Italy
Chronic 15.9 Topiramate (100) Frequency Parallel 24 59 36% 46.1 75%
Mei [84], 2006, Italy Chronic 24 Topiramate (100) Frequency Parallel 12 50 42% 45.8 69%
Silberstein [89],
2007, USA
Chronic 17.0 Topiramate (100) Frequency Parallel 16 306 46% 38.2 85%
Silvestrini [92], 2003,
Italy
Chronic 20 Topiramate (50) Frequency Parallel 8 28 0% 43.5 64%
Yurekli, 2008,
Turkey
Chronic 22 Valproate (1000) Frequency Parallel 12 29 9% 40.4 83%
Beta-Blockers
Palferman [122],
1983, UK
Chronic 12.1 Propranolol (120) Frequency Crossover
(?)
8 22 39% 37.8 73%
Stensrud [131],
1980, Norway
Chronic >15 Atenolol (100)
Propranolol (160)
Frequency Crossover
(1)
6 7 20% ns 69%
Chronic Daily Headache (>15 Headaches/Month)
Anticonvulsants
Beran[68], 2010,
Australia
Chronic Daily Headache 19.6 Levetiracetam (3000) Frequency Crossover
(1)
11 96 30% 48.8 53%
Sarchielli [86], 2014,
Italy
Chronic Daily Headache
(Medication overuse)
21.8 Valproate (800) Frequency Parallel 24 88 17% ns 90%
Spira [93], 2003,
Australia
Chronic Daily Headache 27.4 Gabapentin (2400) Frequency Crossover
(1)
8 133 17% 43 69%
Yurekli [99], 2008,
Turkey
Chronic Daily 22.7 Valproate (1000) Frequency Parallel 12 29 0% 40.4 83%
Selective Serotonin Reuptake Inhibitor
Saper [158], 1994,
USA
Chronic Daily >16 Fluoxetine (40) Frequency Parallel 12 111 5 36.5 87%
Stensrud [131],
1980, Norway
Episodic (n = 21)Chronic
(n = 7)
<15>15 Atenolol (100)
Propranolol (160)
Frequency Crossover
(1)
6 35 20% ns 69%
doi:10.1371/journal.pone.0130733.t003
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Table 4. Quality Ratings of included placebo controlled trials.
Cochrane Risk of Bias
Study Jadad
Score
(0–8)
Intention
to Treat
Adequate
sequence
generation
Adequate
concealed
allocation
Adequate
Blinding
Incomplete
outcome data
addressed
Free of
selective
outcome
reporting
Free of
“other”
bias
Industry
sponsored
EPISODIC MIGRAINES
Alpha Blockers
Adam, 1978, UK 2 No Unclear Unclear Unclear Unclear Unclear Unclear No
Boison, 1978, Sweden 2 No Unclear Unclear Unclear Unclear Unclear Unclear No
Bredfeldt, 1989, USA 5 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Lynggaard, 1975,
Denmark
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Mondrup, 1977,
Denmark
6 No Unclear Unclear Yes Unclear Unclear Unclear No
Ryan, 1975, USA 1 No Unclear Unclear Unclear Unclear Unclear Unclear No
Shafar, 1972, UK 4 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Stensrud, 1976,
Norway
0 No Unclear Unclear Unclear Unclear Unclear Unclear No
Antiogensin Enzyme Converting Inhibitors
Schrader (2001),
Norway, Lisinopril
6 Yes Unclear Unclear Yes Unclear Unclear Unclear Yes
Angiotensin Receptor Blocker
Diener (2009),
Germany, Telmisartan
3 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Trovnik (2003)
Norway, Candesartan
8 Yes Yes Yes Yes Unclear Unclear Unclear Yes
Anticonvulsants
Brandes, 2004,
Canada/USA,
Topiramate
8 Yes Yes Yes Yes Yes Yes Unclear Yes
Cady, 2009, USA,
Carisbamate
8 Yes Yes Yes Yes Unclear Unclear Unclear Yes
de Tommaso, 2007,
Italy, Topiramate,
Levitracetam
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Di’ Trapani, 2000,
Italy, Gabapentin
4 Yes Unclear Unclear Unclear Yes Unclear Unclear Unclear
Diener, 2004 Europe,
Topiramate,
Propropranolol
6 Yes Unclear Unclear Unclear Yes Yes Unclear Yes
Diener, 2007, Italy,
Topiramate
8 No Yes Yes Yes Yes Unclear Unclear Unclear
Edwards, 2003, USA,
Topiramate
4 Yes Unclear Unclear Unclear Yes Unclear Unclear Yes
Freitag, 2002, USA,
divalproex
8 Yes Yes Yes Yes Yes Unclear Unclear Yes
Gupta, 2007, India,
Topiramate
8 Yes Yes Yes Yes Yes Unclear No Unclear
Hering 1992, Israel,
Valproate
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Jensen,1994,
Denmark, Valproate
6 No Unclear Unclear Yes Unclear Unclear Unclear Yes
(Continued)
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Table 4. (Continued)
Cochrane Risk of Bias
Study Jadad
Score
(0–8)
Intention
to Treat
Adequate
sequence
generation
Adequate
concealed
allocation
Adequate
Blinding
Incomplete
outcome data
addressed
Free of
selective
outcome
reporting
Free of
“other”
bias
Industry
sponsored
Klapper,1997, USA,
Divalproex
4 Yes Unclear Unclear Unclear Unclear Unclear Unclear Yes
Lipton, 2011, USA,
Topiramate
8 Yes Yes Yes Yes Yes No Unclear Yes
Mathew, 1995, USA,
Valproate
6 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Mathew, 2001, USA,
Gabapentin
6 Yes Yes Unclear Unclear Unclear Unclear Unclear Yes
Rompel, 1970, S
Africa,
Carbamazepine
5 No Yes Yes Yes Yes Yes Unclear Yes
Silberstein,2004, USA,
Topiramate
6 Yes Yes Yes Unclear Yes Unclear Unclear Yes
Silberstein, 2006,
USA, Topiramate
4 Yes Unclear Unclear Unclear Unclear Unclear Unclear Yes
Silberstein, 2008,
USA, Oxcarbazepine
8 Yes Yes Yes Yes Yes Unclear Unclear Yes
Steiner,1997, UK,
Lamotrigine
6 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Stensrud,1979,
Norway, Clonazepam
2 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Storey,2001, USA,
Topiramate
4 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Vahedi,2002, France,
Acetazolamide
6 Yes Yes Yes Yes Yes Yes Unclear Yes
Beta Blockers
Ahuja, 1985, India,
Propanolol
2 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Al-Qassab, 1993,
England, Propanolol
3 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Andersson, 1983,
Denmark, Metoprolol
2 Yes Unclear Unclear Yes No Unclear Unclear Unclear
Borgesen, 1974,
Denmark, Propranolol
4 No Unclear Unclear Yes No No No Unclear
Dahlof, 1987,
Sweden, Propranolol
5 Yes Unclear Unclear Yes No No No Unclear
Diener, 1996,
Germany, Propranolol,
Clyclandelate
4 Yes Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Diener, 2004,
Germany, Propranolol
6 Yes Unclear Unclear Unclear Yes Yes Unclear Yes
Ekbom, 1972,
Sweden, Pindolol
2 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Ekbom, 1975,
Sweden, Alprenolol
2 No Unclear Unclear Unclear Yes Unclear Unclear Yes
Forssman, 1976,
Sweden, Propranolol
6 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Forssman, 1983,
Sweden, Atenolol
2 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
(Continued)
Meta-Analysis of Prophylactic Treatment of Migraine Headaches
PLOS ONE | DOI:10.1371/journal.pone.0130733 July 14, 2015 15 / 60
Table 4. (Continued)
Cochrane Risk of Bias
Study Jadad
Score
(0–8)
Intention
to Treat
Adequate
sequence
generation
Adequate
concealed
allocation
Adequate
Blinding
Incomplete
outcome data
addressed
Free of
selective
outcome
reporting
Free of
“other”
bias
Industry
sponsored
Freitag, 1984, USA,
Nadolol
3 Yes Unclear Unclear Yes Unclear Unclear Unclear Unclear
Holroyd, 2010, USA,
Propanolol
6 Yes Yes Yes Yes Yes Yes Unclear Unclear
Johannsson, 1987,
Sweden, Atenolol
2 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Johnson, 1986, New
Zealand, Propanolol
3 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Kangasniemi, 1987,
Norway, Metoprolol
0 4 Yes Unclear Unclear Unclear Yes Unclear Unclear
Malvea, 1973, USA,
Propanolol
4 Yes Unclear Unclear Unclear Yes Unclear Unclear Unclear
Mathew, 1981, USA,
Propanolol,
Amitriptyline
2 No Unclear Unclear No No No Yes Unclear
Mikkelsen, 1986,
Denmark, Propanolol
6 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Nadelmann, 1986,
USA, Propanolol
6 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Nanda, 1977,
Scotland, Acebutolol
2 No Unclear Unclear Unclear No Unclear Unclear Yes
Pita, 1977, Spain,
Propranolol
6 No No Unclear Yes Yes Unclear Unclear Yes
Pradalier, 1989,
France, Propranolol
5 Yes Unclear Unclear Yes Unclear Unclear Unclear Unclear
Sargent, 1985, USA,
Propranolol
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Sjaastad, 1972,
Norway, Pindolol
5 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Standnes, 1982,
Norway, Propranolol,
Timolol
4 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Steiner, 1988, UK,
Metoprolol
6 No Unclear Unclear Yes No No Unclear Unclear
Stellar, 1984, USA,
Timolol
7 No Yes Unclear Yes No Unclear Unclear Unclear
Stensrud, 1976,
Norway, Propranolol,
Inderal
5 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Tfelt-Hansen, 1984,
Scandinavia, Timolol,
Propranolol
6 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Van de Ven, 1997,
Denmark, Bisoprolol
4 Yes Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Wideroe, 1974,
Norway, Propranolol
4 No Unclear Unclear Yes No Unclear Unclear Yes
Zeigler, 1987, USA,
Propranolol
3 No Unclear Unclear Yes Yes Unclear Unclear No
Calcium Channel Blockers
(Continued)
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Table 4. (Continued)
Cochrane Risk of Bias
Study Jadad
Score
(0–8)
Intention
to Treat
Adequate
sequence
generation
Adequate
concealed
allocation
Adequate
Blinding
Incomplete
outcome data
addressed
Free of
selective
outcome
reporting
Free of
“other”
bias
Industry
sponsored
Ansell, 1988, UK,
Nimodipine
3 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Gelmers, 1983,
Netherlands,
Nimodipine
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Havanka-Kanniainen,
1985, Finland,
Nimodipine
4 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Leandri, 1990, Italy,
Nicardipine
3 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Markley, 1984, USA,
Verapamil
3 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
McArthur, 1989, USA,
Nifedipine
3 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Nimodipine European
Migraine (with aura)
Trial, 1989, EU,
Nimodipine
2 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Nimodipine European
Migraine (Without
aura) trial (1989), EU,
Nimodipine
5 Yes Unclear Unclear Yes Unclear Unclear Unclear Unclear
Shukla, 1995, UK,
Nifedipine
5 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Solomon, 1983, USA,
Verapamil
5 No Unclear Unclear Yes No No Unclear Yes
Stewart, 1988,
Canada, Nimodipine
2 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Flunarazine
Diamond, 1993, USA, 2 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Frenken, 1984,
Netherlands,
Flunarizine
6 Yes Unclear Unclear Yes Yes Unclear Unclear Yes
Louis, 1981, Belgium,
Flunarizine
5 Yes Unclear Unclear Yes Yes Yes Unclear No
Mendenopoulos,
1985, Greece,
Flunarizine
7 Yes Yes Yes Yes Yes Unclear Unclear Yes
Pini, 1986, Italy,
Flunarizine
2 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Sorensen, 1986,
Denmark, Flunarizine
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Thomas, 1991, India,
Flunarizine
3 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Selective Serotonin Reuptake Inhibitors
Adly, 1993, USA,
Fluoxetine
2 No Unclear Yes Unclear No No Unclear Unclear
d'Amato, 1999, Italy,
Fluoxetine
5 No Unclear Unclear Yes No No Unclear Unclear
(Continued)
Meta-Analysis of Prophylactic Treatment of Migraine Headaches
PLOS ONE | DOI:10.1371/journal.pone.0130733 July 14, 2015 17 / 60
Table 4. (Continued)
Cochrane Risk of Bias
Study Jadad
Score
(0–8)
Intention
to Treat
Adequate
sequence
generation
Adequate
concealed
allocation
Adequate
Blinding
Incomplete
outcome data
addressed
Free of
selective
outcome
reporting
Free of
“other”
bias
Industry
sponsored
Landy, 1998, USA,
Sertaline
3 No Unclear Unclear Unclear No No Unclear No
Steiner, 1998, UK, s-
Fluoxetine
6 No Unclear Unclear Yes No No Unclear Unclear
Zeeberg, 1981,
Sweden, Femoxitine
2 No No No No Unclear Unclear Unclear Unclear
Serotonin Norepinephrine Reuptake Inhibitor
Ozyalcin, 2004,
Turkey, Venlafaxine
3 No Unclear Unclear Unclear No No Unclear Yes
Serotonin Agonist (Pizotifen)
Arthur, 1971, New
Zealand, Pizotifen
2 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Bellavance, 1990,
Canada, Pizotifen
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Carroll, 1975, UK,
Pizotifen
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Cleland, 1997, UK,
Pizotifen
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Hughes, 1971, UK,
Pizotifen
4 Yes Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Kangasniemi, 1979,
Finland, Pizotifen
4 Yes Unclear Unclear Unclear Yes Unclear Unclear Unclear
Lance, 1968, Pizotifen
Lawrence, 1977, UK,
Pizotifen
4 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Osterman, 1977,
Sweden, Pizotifen
5 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Ryan, 1968, USA,
Pizotifen
5 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Tricyclic Antidepressants
Couch, 1976, USA,
Amitriptyline
3 No Unclear Unclear Yes No Unclear Yes Yes
Couch, 1979,
Amitriptyline
6 No Unclear Unclear Yes No Unclear Unclear Yes
Couch, 2011, USA,
Amitriptyline
8 No Yes Yes Yes No Unclear Unclear Yes
Gomersall, 1973, UK,
Amitriptyline
3 No Unclear Unclear Unclear No No Yes Yes
Jacobs, 1972, UK,
Opipramol
4 No Unclear Yes Yes No No Yes Yes
Langohr, 1985,
Germany,
Clomipramine
4 No Unclear Unclear Unclear No No Yes Yes
Morland, 1979,
Norway, Doxepin
3 No Unclear Unclear Unclear No Unclear Yes Unclear
Noone, 1980, UK,
Clomipramin
4 No Yes Yes Unclear No Unclear Yes Yes
Ziegler, 1987, USA,
Amitriptyline
3 No Unclear Unclear Yes Yes Unclear Unclear No
(Continued)
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Table 4. (Continued)
Cochrane Risk of Bias
Study Jadad
Score
(0–8)
Intention
to Treat
Adequate
sequence
generation
Adequate
concealed
allocation
Adequate
Blinding
Incomplete
outcome data
addressed
Free of
selective
outcome
reporting
Free of
“other”
bias
Industry
sponsored
CHRONIC MIGRAINES
Alpha-blockers
Saper, 2002, USA 6 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Anticonvulsants
Diener, 2007, Italy,
Topiramate
8 No Yes Yes Yes Yes Unclear Unclear Unclear
Mei, 2006, Italy,
Topiramate
4 Yes Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Silberstein, 2007,
USA, Topiramate
8 Yes Yes Yes Yes Yes Unclear Unclear Yes
Silvestrini, 2003, Italy,
Topiramate
4 Yes Unclear Unclear Unclear Yes Unclear Unclear Unclear
Beta Blockers
Palferman, 1983, UK,
Propranolol
3 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
CHRONIC DAILY HEADACHE
Anticonvulsants
Beran, 2010,
Australia,
Levetiracetam
5 No Yes Yes Unclear Unclear Unclear Unclear Yes
Spira, 2003, Australia,
Gabapentin
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Yurekli, 2008, Turkey,
Valproate
4 No Unclear Unclear Yes Yes Unclear Unclear Unclear
Selective Serotonin Reuptake Inhibitors
Saper, 1994, USA,
Fluoxetine
8 No Yes Yes Yes Unclear Unclear Unclear Yes
MIXED (CHRONIC + EPISODIC)
Anticonvulsants
Ghose, 2002, New
Zealand, Vigabatrin
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Beta Blockers
Stensrud, 1980,
Norway, Atenolol
5 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Unclear Migraine Headache Type
Beta Blockers
Freitag, 1984, USA,
Nadolol
3 Yes Unclear Unclear Yes Unclear Unclear Unclear Unclear
Mathew, 1981, USA,
Propranolol,
Amitriptyline
2 No Unclear Unclear No No No Yes Unclear
Nadelmann, 1986,
USA, Propranolol
6 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Weber, 1972, USA,
Propranolol
3 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Selective Serotonin Reuptake Inhibitors
(Continued)
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average rate of withdrawals was 23%. Studies averaged 15 weeks (range 4–82) with a mean of
153 participants (range 23–487). All of the studies reported headache frequency as their out-
come. The two most commonly tested anticonvulsants were topiramate (n = 12) and valproate
(n = 6). Other anticonvulsants tested included acetazolamide (n = 1), carbamazepine (n = 1),
carisbamate (n = 1), clonazepam (n = 1), gabapentin (n = 4), lamotrigine (n = 1), levetiracetam
(n = 3), oxcarbazepine (n = 1), and vigabatrin (n = 1).
In single trials, several anticonvulsants were no better than placebo for episodic migraines
including acetazolamide, carbamazepine, carisbamate, clonazepam, oxcarbazepine and vigaba-
trin (Table 5). In single trials, lamotrigine was found effective at 4 weeks though ineffective at
12 weeks (Table 5). In several trials, gabapentin was not superior to placebo (Table 5). Several
of these anticonvulsants were assessed for ability to reduce headaches by 50% (Table 7). Caris-
bamate was less effective than placebo and anticonvulsants no more likely than placebo to
reduce headaches by at least 50% included acetazolamide, gabapentin, lamotrigine, levetirace-
tam and oxcarbazepine.
Anticonvulsants that were found to be more effective than placebo for episodic migraine
included levetiracetam (Table 6), topiramate (Fig 4) and valproate (Fig 5). Both topiramate and
valproate had numerous trials demonstrating benefit at multiple time points (Table 5).
Topiramate. Topiramate has been evaluated in twelve placebo-controlled trials that
reported outcomes at numerous time points and different doses (50, 100 and 200mg). Pooled
results suggest that topiramate was more effective than placebo at all time points (4–24 weeks,
Table 5) and at all doses assessed. There was evidence that higher doses of topiramate was
more effective than lower ones, with a stepwise increase as the dose increased from 50 to 100 to
200mg (Fig 6). For chronic migraine, 2 studies of topiramate suggested effectiveness for up to
16 weeks (Table 6). In several studies (n = 8) topiramate was also demonstrated to be more
effective than placebo at reducing migraine by more than 50% (Table 7).
Valproate. Valproate also had been compared to placebo in six trials with multiple time
points and varying doses (500-1500mg). Valproate was found to be more effective than placebo
for episodic migraine at all time points assessed including 4, 8 and 12 weeks (Table 5, Fig 5).
However, unlike topiramate there was no evidence of a difference in response to increased
doses (dose-response p = 0.83). Valproate was also found in numerous trials (n = 5) to reduce
headaches by more than 50% (Table 7).
Beta Blockers. There were 38 trials comparing beta-blockers to placebo with a total of
2019 participants, 37 focusing on episodic (Table 2) and 1 on chronic migraine headaches
(Table 3). The average rate of withdrawals was 18%. Study duration averaged 11 weeks (range
4–64) with a mean of 64 participants (range 20–568). The majority (82%) reported headache
frequency, four trials used headache index, and one duration. There were a variety of beta-
Table 4. (Continued)
Cochrane Risk of Bias
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Saper, 1994, USA,
Fluoxetine
8 No Yes Yes Yes Unclear Unclear Unclear Yes
Tricyclic Antidepressants
Mathew, 1981, USA,
Amitriptyline
2 No Unclear Unclear No No No Yes Unclear
doi:10.1371/journal.pone.0130733.t004
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Table 5. Placebo Controlled Randomized Clinical Trials of Continuous Outcomes among patients with episodic migraines (<15 headaches/
month).
Drug Time Point
(weeks)
Metric Study (Year) Pooled Mean Difference
(95% CI)
Heterogeneity
Alpha Blockers
Clonidine 8 Headaches/month Boisen (1978) -0.09 (-0.99 to 0.80)
8 Headaches/month Bredfeldt (1989) -0.96 (-2.6 to 0.64)
8 Headaches/month Ryan (1975) -0.46 (-2.7 to 1.8)
8 Headaches/month Shafar (1972) -0.72 (-1.6 to 0.14)
8 Headaches/month Stensrud (1976) -1.0 (-3.1 to 1.1)
8 Pooled (HA/Month): -0.52 (-1.06 to 0.02) Q = 1.57, df = 4, I2 = 0.0%
12 Headaches/month Lynggaard (1975) -0.37 (-3.4 to 2.)
12 Headaches/month Mondrup (1977) 1.1 (-2.5 to 4.8)
12 Pooled (HA/Month): 0.24 (-2.1 to 2.6) Q = 0.38, df = 1, I2 = 0.0%
24 Headaches/month Adam (1978) 0.00 (-0.47 to 0.47)
Angiotensin Converting Enzyme Inhibitors
Enalapril 4 Headaches/month Sonbolestan (2013) -2.4 (-7.5 to 2.7)
Enalapril 8 Headaches/month Sonbolestan (2013) -0.83 (-6.2 to 4.5)
Lisinopril 12 Headaches/month Schrader (2001) -1.4 (-2.6 to -0.2)
Captopril 16 Headache Index Paterna (1992) -0.86 (-1.5 to -0.21)
Angiotensin Receptor Blockers
Candesaran 12 Headaches/month Stovner (2013) -0.58 (-1.4 to 0.23)
12 Headaches/month Trovnik (2003) -1.6 (-3.0 to -0.16)
12 Pooled (HA/Month) -0.9 (-1.8 to 0.03) Q = 1.46, df = 1, I2 =
31.7%
Telmisartan 12 Headaches/month Diener (2009) -1.9 (-3.6 to -0.23) —
12 Pooled (HA/Month) -1.1 (-1.9 to -0.27) Q = 2.82, df = 3 I2 =
29.1%
Anticonvulsants
Acetazolamide 12 Headaches/month Vahedi (2002) 0.5 (-1.7 to 2.7)
Carbamazipine 6 Headaches/month Rompel (1970) -3.2 (-6.6 to 0.20)
Carisbamate 14 Headaches/month Cady (2009) -0.09 (-0.34 to 0.17)
Clonazepam 4 Headaches/month Stensrud (1979) -3.6 (-7.2 to 0.03))
Gabapentin 4 Headaches/month Di’Trapani -0.2 (-1.6 to 1.2)
8 Headaches/month Di”Trapani -1.1 (-2.5 to 0.34)
12 Headaches/month Di’ Trapani (2000) -1.9 (-3.4 to -0.41)
12 Headaches/month Mathew (2001) -0.2 (-0.89 to 0.49)
12 Pooled (HA/Month) —0.92 (-2.6 to 0.74) Q = 4.1, df = 2, I2 = 75.6%
20 Headaches/month Silberstein (2013) -0.33 (-0.71 to 0.04)
Lamotrigine 4 Headaches/month Gupta (2006) -1.2 (-2.2 to -0.18)
12 Headaches/month Steiner (1997) 0.20 (-0.36 to 0.76)
Levetiracetam 8 Headaches/month De Tommaso (2007) -4.2 (-7.2 to -1.3)
12 Headaches/month Verma (2013) -2.2 (-3.0 to -1.3)
Pooled (HA/Month) -2.7 (-4.4 to -0.97) Q = 1.69, df = 1 I2 =
40.9%
Oxcarbazepine 15 Headaches/month Silberstein (2008) 0.17 (-0.13 to 0.47)
Topiramate 4 (50 mg/day) Headaches/month Brandes (2004) -0.75 (-1.4 to -0.06)
4 (50 mg/day) Headaches/month Gupta (2006) -2.1 (-3.0 to -1.1)
4 (50 mg/day) Headaches/month Silberstein (2004) -1.0 (-1.9 to– 0.13)
4 (50 mg/day) Headaches/month Silvestrini (2003) -5.0 (-9.2 to -0.8)
4 (50 mg/day) Pooled (HA/Month) -1.4 (-2.2 to -0.5) Q = 7.81, df = 3, I2 =
43.0%
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Table 5. (Continued)
Drug Time Point
(weeks)
Metric Study (Year) Pooled Mean Difference
(95% CI)
Heterogeneity
Topiramate 4 (100 mg/day) Headaches/month Brandes (2004) -0.80 (-1.4 to -0.18)
4 (100 mg/day) Headaches/month Diener (2004) -1.1 (-1.9 to -0.2)
4 (100 mg/day) Headaches/month Silberstein (2004) -0.9 (-1.7 to -0.14)
4 (100 mg/day) Pooled (HA/Month) -0.89 (-1.3 to -0.48) Q = 0.23, df = 2, I2 = 0.0%
4 (200 mg/day) Headaches/month Brandes (2004) -1.9 (-2.4 to -1.3)
4 (200 mg/day) Headaches/month Edwards (2003) -0.60 (-1.1 to -0.13)
4 (200 mg/day) Headaches/month Silberstein (2004) -1.4 (-2.2 to -0.62)
4 (200 mg/day) Headaches/month Silberstein (2006) -0.9 (-2.3 to 0.55)
4 (200 mg/day) Pooled (HA/Month) -0.91 (-1.3 to -0.48) Q = 12.07, df = 3
I2 = 75.1%
4 (all doses) Pooled (HA/Month) -1.1 (-1.5 to-0.79) Q = 21.3, df = 10, I2 =
53%
8 (50 mg/day) Headaches/month Brandes (2004) -0.50 (01.2 to 0.19)
8 (50 mg/day) Headaches/month Silberstein (2004) -0.80 (-1.4 to -0.20)
8 (50 mg/day) Headaches/month Silberstein (2006) -12.5 (-17.1 to -7.9)
8 (50 mg/day) Headaches/month Pooled (HA/Month) -2.3 (-4.4 to -0.23) Q = 25.56, df = 2, I2 =
92.2%
8 (100 mg/day) Headaches/month Brandes (2004) -0.8 (-1.4 to -0.18)
8 (100 mg/day) Headaches/month De Tammosa (2007) -5.2 (-7.8 to -2.5)
8 (100 mg/day) Headaches/month Diener (2004) -0.85 (-2.1 to 0.39)
8 (100 mg/day) Headaches/month Silberstein (2004) -1.1 (-1.7 to -0.53)
8 (100 mg/day) Pooled (HA/Month) -1.3 (-2.2 to -0.43) Q = 10.18, df = 3, I270.5%
8 (200 mg/day) Headaches/month Brandes (2004) -1.8 (-2.3 to -1.3)
8 (200 mg/day) Headaches/month Silberstein (2004) -1.5 (-2.1 to -0.9)
8 (200 mg/day) Headaches/month Silberstein (2006) -0.30 (-1.7 to 1.1)
8 (200 mg/day) Pooled (HA/Month) -1.5 (-2.1 to -0.87) Q = 3.68, df = 2, I2 =
45.7%
8 (All Doses) Pooled (HA/Month) -1.3 (-1.9 to -0.7) Q = 46.42, df = 9, I2 =
80.6%
12 (50 mg/day) Headaches/month Brandes (2004) -0.40 (-1.1 to 0.29)
12 (50 mg/day) Headaches/month Silberstein (2004) -0.70 (-1.4 to 0.02)
12 (50 mg/day) Pooled (HA/Month): -0.54 (-1.0 to -0.05) Q = 0.39, df = 2, I2 = 0.0%
12 (100 mg/day) Headaches/month Brandes (2004) -0.75 (-1.4 to -0.13)
12 (100 mg/day) Headaches/month Diener (2004) -0.90 (-2.2 to 0.39)
12 (100 mg/day) Headaches/month Silberstein (2004) -1.1 (-2.0 to -0.19)
12 (100 mg/day) Pooled (HA/Month): -0.87 (-1.3 to -0.39) Q = 1.52, df = 2, I2 = 0.0%
12 (200 mg/day) Headaches/month Brandes (2004) -1.7 (-2.2 to -1.1)
12 (200 mg/day) Headaches/month Silberstein (2004) -1.4 (-2.2 to -0.59)
12 (200 mg/day) Headaches/month Silberstein (2006) -0.70 (-2.1 to 0.75)
12 (200 mg/day) Pooled (HA/Month): -1.5 (-1.9 to -1.1) Q = 0.35, df = 1, I2 = 0.0%
12 (All doses) Pooled (HA/Month): -0.99 (-1.3 to -0.64) Q = 0.04, df = 1, I2 = 0.0%
16 (50 mg/day) Headaches/month Brandes (2004) -0.50 (-1.2 to 0.19)
16 (50 mg/day) Headaches/month Silberstein (2004) -0.40 (-1.1 to 0.33)
16 (50 mg/day) Pooled (HA/Month): -0.45 (-0.95 to 0.05) Q = 0.04, df = 1, I2 = 0.0%
16 (100 mg/day) Headaches/month Brandes (2004) -0.70 (-1.3 to -0.08)
16 (100 mg/day) Headaches/month Diener (2004) -1.1 (-2.4 to 0.24)
16 (100 mg/day) Headaches/month Silberstein (2004) -1.2 (-2.0 to -0.38)
16 (100 mg/day) Headaches/month Silberstein (2007) -1.5 (-3.1 to 0.06)
16 (100 mg/day) Pooled (HA/Month): -0.95 (-1.4 to -0.51) Q = 1.51, df = 3, I2 = 0.0%
16 (200 mg/day) Headaches/month Brandes (2004) -1.6 (-2.1 to -1.1)
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Table 5. (Continued)
Drug Time Point
(weeks)
Metric Study (Year) Pooled Mean Difference
(95% CI)
Heterogeneity
16 (200 mg/day) Headaches/month Silberstein (2004) -1.3 (-2.2 to -0.45)
16 (200 mg/day) Headaches/month Silberstein (2006) -0.05 (-1.5 to 1.4)
16 (200 mg/day) Headaches/month Storey (2001) -0.52 (-1.67 to 0.63)
16 (200 mg/day) Pooled (HA/Month): -1.0 (-1.7 to -0.44) Q = 5.76, df = 3, I2 =
47.9%
16 (All doses) Pooled (HA/Month): -0.92 (-1.2 to -0.59) Q = 13.41, df = 9, I2 =
32.9%
20 (50mg/day) Headaches/month Brandes (2004) -0.50 (-1.2 to 0.19)
20 (50mg/day) Headaches/month Silberstein (2004) -0.55 (-1.5 to 0.40)
20 (50mg/day) Pooled (HA/Month): -0.52 (-1.1 to 0.04) Q = 0.01, df = 1, I2 = 0.0%
20 (100 mg/day) Headaches/month Brandes (2004) -0.70 (-1.3 to -0.08)
20 (100 mg/day) Headaches/month Diener (2004) -1.2 (-2.6 to 0.17)
20 (100 mg/day) Headaches/month Silberstein (2004) -1.4 (-2.3 to -0.39)
20 (100 mg/day) Pooled (HA/Month): -0.93 (-1.4 to -0.44) Q = 1.42, df = 2, I2 = 0.0%
20 (200 mg/day) Headaches/month Brandes (2004) -1.5 (-2.0 to -0.95)
20 (200 mg/day) Headaches/month Silberstein (2004) -1.4 (-2.3 to -0.36)
20 (200 mg/day) Headaches/month Silberstein (2006) -0.50 (-1.9 to 0.95)
20 (200 mg/day) Pooled (HA/Month): -1.4 (-1.8 to 0.92) Q = 1.61, df = 2, I2 = 0.0%
20 (all doses) Pooled (HA/Month): -0.98 (-1.3 to -0.66) Q = 8.52, df = 7, I2 =
17.8%
24 (50 mgday) Headaches/month Brandes (2004) -0.40 (-1.2 to 0.44)
24 (50 mgday) Headaches/month Silberstein (2004) -0.50 (-1.5 to 0.48)
24 (50 mgday) Pooled (HA/Month): -0.44 (-1.1 to 0.20) Q = 0.02, df = 1, I2 = 0.0%
24 (100 mg/day) Headaches/month Brandes (2004) -1.0 (-1.8 to -0.18)
24 (100 mg/day) Headaches/month Lipton (2011) -1.4 (-2.2 to -0.60)
24 (100 mg/day) Headaches/month Silberstein (2004) -1.3 (-2.3 to -0.34)
24 (100 mg/day) Pooled (HA/Month): -1.2 (-1.7 to -0.74) Q = 0.49, df = 2, I2 = 0.0%
24 (200 mg/day) Headaches/month Brandes (2004) -1.5 (-2.2 to -0.84)
24 (200 mg/day) Headaches/month Silberstein (2004) -1.3 (-2.3 to -0.31)
24 (200 mg/day) Pooled (HA/Month): -1.4 (-2.0 to -0.89) Q = 0.11, df = 1, I2 = 0.0%
24 (All doses) Pooled (HA/Month): -1.1 (-1.4 to -0.77) Q = 6.4, df = 6, I2 = 6.4%
Valproate 4 Headaches/month Freitag (2002) -0.20 (-0.61 to 0.21)
4 Headaches/month Klapper (1997) -1.8 (-2.6 to -0.95)
4 Headaches/month Mathew (1995 -1.8 (-3.6 to -0.03)
4 Pooled (HA/Month): -1.4 (-2.2 to -0.56) Q = 14.48, df = 2, I2 =
51.6%
8 Headaches/month Freitag (2002) -0.25 (-0.51 to 0.01)
8 Headaches/month Hering (1992) -6.8 (-12.10 to -1.5)
8 Headaches/month Klapper (1997) -1.6 (-2.3 to -0.95)
8 Headaches/month Mathew (1995) -2.1 (-3.6 to -0.56)
8 Pooled (HA/Month): -1.5 (-2.2 to -0.76) Q = 17.35, df = 3. I2 =
42.6%
12 Headaches/month Freitag (2002) -0.45 (-0.86 to -0.04)
12 Headaches/month Jensen (1994) -2.6 (-5.5 to 0.26)
12 Headaches/month Klapper (1997) -1.7 (-2.4 to -0.96)
12 Headaches/month Mathew (1995) -2.8 (-4.8 to -0.74)
12 Pooled (HA/Month): -1.5 (-2.1 to -0.80) Q = 24.7, I2 = 63.6%
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Table 5. (Continued)
Drug Time Point
(weeks)
Metric Study (Year) Pooled Mean Difference
(95% CI)
Heterogeneity
Vigabatrin 4 Headaches/month Ghose (2002) -0.54 (-1.9 to 0.77)
8 Headaches/month Ghose (2002) -0.27 (-2.3 to 1.7)
12 Headaches/month Ghose (2002) -0.42 (-2.3 to 1.6)
Beta-Blockers
Acebutolol 4 Headaches/month Nanda (1977) 0.10 (-0.75 to 0.95)
8 Headaches/month Nanda (1977) -0.50 (-1.35 to 0.35)
12 Headaches/month Nanda (1977) -0.68 (-1.68 to 0.32)
Alprenolol 8 Headaches/month Ekbom (1975) 0.20 (-0.91 to 1.3)
Atenolol 8 Headaches/month Stensrud (1980) -1.5 (-3.0 to -0.04)
12 Headaches/month Forssman (1983) -5.4 (-12.6 to 1.8)
12 Headaches/month Johansson (1987) -2.05 (-3.76to -0.48)
12 Pooled SMD -2.2 (-3.7 to -0.67) Q = 0.80, df = 1, I2 = 0.0%
Bisoprolol 4 Headaches/month Van de Ven (1997) -0.40 (-0.87 to 0.07)
8 Headaches/month Van de Ven (1997) -0.61 (-1.1 to -0.16)
Metoprolol 4 Headaches/month Langor (1985) -0.63 (-1.5 to 0.25)
8 Headaches/month Andersson (1983) -1.5 (-2.4 to -0.60)
8 Headaches/month Kangasniemi (1987) -0.70 (-1.4 to -0.03)
8 Headaches/month Steiner (1987) -0.80 (-1.7 to 0.13)
8 Pooled HA/Month -0.94 (-1.4 to -0.46) Q = 1.02, I2 = 0.0%
Oxprenolol 8 Headaches/month Ekbom (1977) -080 (-3.9 to 2.3)
Pindolol 4 Headaches/month Ekbom (1972) 2.9 (-1.0 to 6.8)
4 Headaches/month Sjaastad (1972) 1.5 (-5.5 to 2.6)
4 Pooled HA/Month 1.2 (-2.5 to 4.9) Q = 0.49, I2 = 0.0%
Propranolol 4 Headaches/month Dahlof (1987) -1.1 (-2.2 to 0.05)
4 Headaches/month Diener (2004) -1.1 (-1.9 to -0.28)
4 Headaches/month Pradalier (1989) -1.5 (-2.1 to -0.87)
4 Headaches/month Stensrud (1976) -1.1 (-3.5 to 1.3)
4 Pooled HA/Month -1.1 (-1.5 to -0.74) Q = 3.44, df = 3, I2 =
0.00%
4 Headache Index Zeigler (1987) -0.68 (-1.4 to 0.06)
8 Headaches/month Ahuja (1985) -5.9 (-11.4 to -0.37)
8 Headaches/month Al-Qassab (1993) 0.6 (-2.84 to 4.0)
8 Headaches/month Diener (2004) -0.8 (-1.6 to -0.005)
8 Headaches/month Holroyd (2010) -0.6 (-1.3 to 0.12)
8 Headaches/month Pita (1977) -5.3 (-8.7 to -1.8)
8 Pooled HA/Month -1.0 (-2.1 to -0.39) Q = 11.08, df = 4, I2 =
54.9%
8 Headache index Nadelmann (1986) -0.54 (-1.11 to 0.04)
12 Headaches/month Borgesen (1974) -0.30 (-1.1 to -0.48)
12 Headaches/month Diener (2004) -0.80 (-1.6 to -0.02)
12 Headaches/month Forssman (1976) -1.8 (-3.9 to 0.4)
12 Headaches/month Holroyd (2010) -0.8 (-1.5 to -0.08)
12 Headaches/month Johnson (1986) -6.3 (-16.6 to 3.9)
12 Headaches/month Mikkelsen (1986) -2.4 (-7.9 to 3.1)
12 Headaches/month Pradalier (1989) -3.3 (-3.9 to -2.6)
12 Headaches/month Standnes (1982) -1.4 (-2.7 to -0.12)
12 Headaches/month Stovner (2013) -0.62 (-1.4 to 0.16)
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Table 5. (Continued)
Drug Time Point
(weeks)
Metric Study (Year) Pooled Mean Difference
(95% CI)
Heterogeneity
12 Headaches/month Tfelt-Hansen (1983) -1.2 (-2.8 to 0.45)
12 Headaches/month Wideroe (1974) -1.3 (-1.8 to -0.78)
12 Pooled HA/Month -1.3 (-2.0 to -0.62) Q = 46.35, df = 10, I2 =
78.4%
12 Headache hours/month Diener (1996) -12.9 (-31.8 to 5.9)
16 Headaches/month Diener (2004) -1.1 (-2.2 to -0.01)
16 Headaches/month Holroyd (2010) -0.90 (-2.6 to -0.19)
16 Headaches/month Sargent (1985) 0.5 (-0.22 to 1.2)
Pooled HA/Month -0.46 (-1.5 to 0.57) Q = 9.40, df = 2, I2 =
78.7%
20 Headaches/month Diener (2004) -1.5(-2.9 to -0.03)
20 Headaches/month Holroyd (2010) -0.9 (-1.6 to -0.18)
20 Pooled HA/Month -1.0 (-1.7 to -0.37) Q = 0.52, df = 1, I2 = 0.0%
Tomolol 8 Headaches/month Briggs (1979 -2.3 (-5.2 to 0.63)
8 Headaches/month Stellar (1984) -0.70 (-1.5 to 0.07)
8 Pooled HA/Month -0.85 (-1.8 to 0.07) Q = 1.01, df = 1, I2 = 6.8%
12 Headaches/month Standnes (1982) -1.9 (-3.2 to -0.54)
12 Headaches/month Tfelt-Hansen (1984) -1.5 (-3.0 to 0.05)
12 Headaches/month Pooled HA/Month -1.7 (-2.7 to -0.70) Q = 0.12, df = 1, I2 = 0.0%
Calcium Channel Blockers
Cyclendelate 12 Headache duration/month
(hours)
Diener (1996) 15.0 hours (-5.3 to 35.3)
Nicardipine 8 Headaches/month Leandri (1990) -1.6 (-3.3 to 0.15)
Nifedipine 4 Headaches/month McArthur (1989) -0.20 (-0.72 to 0.32)
4 Headaches/month Shukla (1995) -3.8 (-4.8 to -2.8)
4 Pooled HA/Month -2.0 (-5.5 to 1.6) Q = 2.92, df = 1, I2 =
65.8%
8 Headaches/month McArthur (1989) -0.20 (-0.72 to 0.32)
12 Headaches/month McArthur (1989) -0.40 (-1.4 to 0.66)
Nimodipine 4 Headaches/month Gelmers (1983) -0.13 (-0.64 to 0.38)
4 Headaches/month MINES (1989) 0.48 (-0.47 to 0.46)
4 Headaches/month MINES (1989) 0.10 (-0.21 to 0.41)
4 Headaches/month Stewart (1988) -0.31 (-3.3 to 2.7)
4 Pooled HA/Month -0.07 (-0.28 to 0.13) Q = 1.51, df = 3, I2 = 0.0%
4 Headache Index Ansell (1988) -0.36 (-0.88 to 0.16)
8 Headaches/month Gelmers (1983) -1.5 (-2.4 to -0.73)
8 Headaches/month Havanka (1985) -2.2 (-4.2 to -0.24)
8 Headaches/month MINES (1989) 0.17 (-0.54 to 0.88)
8 Headaches/month MINES (1989) 0.94 (-0.45 to 2.32)
8 Headaches/month Stewart (1988) -3.4 (-5.7 to -1.1)
8 Pooled HA/Month -0.98 (-2.3 to 0.30) Q = 22.35, df = 4, I2 =
82.1%
8 Headache Index Ansell (1988) -0.48 (-1.01 to 0.05)
12 Headaches/month Gelmers (1983) -1.3 (-1.9 to -0.69)
12 Headaches/month MINES (1989) 0.74 (0.03 to 1.5)
12 Headaches/month MINES (1989) -0.01 (-1.4 to 1.4)
12 Headaches/month Stewart (1988) -2.8 (-5.2 to -0.48)
12 Pooled HA/Month -0.65 (-2.0 to 0.74) Q = 22.41,df-, I2 = 86.6%
12 Headache Index Ansell (1988) 0.16 (-0.36 to 0.68)
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Table 5. (Continued)
Drug Time Point
(weeks)
Metric Study (Year) Pooled Mean Difference
(95% CI)
Heterogeneity
Verapamil 4 Headaches/month Solomon (1983) -2.9 (-7.8 to 1.9)
8 Headaches/month Markley (1984) -0.60 (-1.4 to 0.19)
Flunarizine
Flunarizine 4 Headaches/month Diamond (1993) 0.60 (-0.35 to 0.47)
4 Headaches/month Frenken (1984) -1.3 (-2.4 to -0.24)
4 Pooled Ha/Month -0.53 (-1.8 to 0.79) Q = 5.51, df = 1, I2 =
81.9%
4 Headache Index Mendenopoulos
(1985)
-0.63 (1.5 to 0.27)
4 Headache Index Pini (1986) 0.19 (-0.73 to 1.1)
4 Headache Index Pooled SMD -0.23 (-1.0 to 0.58) Q = 1.56, df = 1, I2 =
35.8%
4 Overall Pooled SMD -0.27 (-0.76 to 0.23) Q = 6.15, df = 3, I2 =
51.2%
8 Headaches/month Diamond (1993) -0.44 (-1.7 to 0.78)
8 Headaches/month Frenken (1984) -1.9 (-3.5 to -0.31)
8 Pooled Ha/Month -1.1 (-2.5 to 0.34) Q = 2.04, df = 1, I2 =
51.1%
8 Headache Index Mendenopoulos
(1985)
-1.2 (-2.1 to -0.2)
8 Overall Pooled SMD -0.60 (-1.2 to 0.005) Q = 4.92, df = 2, I2 =
59.3%
12 Headaches/month Diamond (1993) -0.61 (-1.8 to 0.65)
12 Headaches/month Frenken (1984) -1.8 (-3.3 to -0.38)
12 Headaches/month Louis (1981) -1.1 (-1.7 to -0.6)
12 Pooled Ha/Month -1.1 (-1.6 to -0.67) Q = 1.39, df = 2, I2 = 0.0%
12 Headache Index Mendenopoulos
(1985)
-1.6 (-2.6 to -0.6)
12 Headache Index Thomas (1989) -0.87 (2.0 to 0.24)
12 Headache Index Pooled SMD -1.3 (-2.0 to -0.52) Q = 0.94, df = 1, I2 = 0.0%
12 Overall Pooled SMD -0.84 (-1.3 to -0.34) Q = 10.33, df = 4, I2 =
61.3%
16 Headaches/month Diamond (1993) -1.2 (-2.1 to -0.24)
16 Headaches/month Sorensen (1986) -1.2 (-2.7 to 0.37)
16 Pooled Ha/Month -1.2 (-2.0 to -0.38)
20 Headaches/month Diamond (1993) -0.36 (-2.4 to 1.69)
Selective Serotonin Reuptake Inhibitors
4 Headaches/month Orholm (1986) -0.20 (-1.3 to 0.93)
4 Headaches/month Zeeberg (1981 0.00 (-1.8 to 1.8)
Femoxitine 4 Pooled Ha/Month -0.14 (-1.1 to 0.81) Q = 0.03, df = 1, I2 = 0.0%
8 Headaches/month Orholm (1986) -0.10 (-1.2 to 1.0)
8 Headaches/month Zeeberg (1981) -1.8 (-3.6 to -0.04)
8 Pooled Ha/Month —0.81 (-2.5 to 0.83) Q = 2.53, df-1, I2 = 60.4%
12 Headaches/month Orholm (1986) 0.50 (-0.63 to 1.6)
12 Headaches/month Zeeberg (1981) -1.4 (-3.2 to 0.36)
12 Pooled Ha/Month -0.33 (-2.2 to 1.5) Q = 3.16, df = 1, I2 =
68.3%
16 Headaches/month Orholm (1986) 0.30 (-0.83 to 1.4)
(Continued)
Meta-Analysis of Prophylactic Treatment of Migraine Headaches
PLOS ONE | DOI:10.1371/journal.pone.0130733 July 14, 2015 26 / 60
Table 5. (Continued)
Drug Time Point
(weeks)
Metric Study (Year) Pooled Mean Difference
(95% CI)
Heterogeneity
Fluoxetine 4 Headache index Adly (1993) -0.34 (-1.27 to 0.59)
4 Headache index d’Amato (1999) -0.08 (-0.63 to 0.48)
4 Headaches/month Steiner (1998) -0.71 (-1.36 to -0.06)
4 Pooled SMD -0.35 (-0.75 to 0.05) Q = 2.11, df = 3, I2 = 5.2%
8 Headache index Adly (1993) -0.74 (-1.70 to 0.22)
8 Headache index d’Amato (1999) -0.01 (-0.56 to 0.55)
8 Headaches/month Steiner (1998) -0.32 (-0.98 to 0.35)
8 Pooled SMD -0.23 (-0.63 to 0.16) Q = 1.76, I2 = 0.0%
12 Headache index Adly (1993) -1.02 (-2.01 to -0.03)
12 Headache index d’Amato (1999) -0.32 (-0.88 to 0.24)
12 Headaches/month Steiner (1998) -0.74 (-1.44 to -0.03)
12 Pooled SMD -0.57 (-0.97 to -0.17) Q = 1.77, df = 2, I2 = 0.0%
16 Headache index d’Amato (1999) -0.64 (-1.22 to -0.07)
20 Headache index d’Amato (1999) -0.32 (-0.88 to 0.24)
Sertraline 4 Headache index Landy (1999) 0.44 (-0.59 to 1.5)
8 Headache index Landy (1988) 0.08 (-0.94 to 1.09)
Pooled SMD (12 weeks) -0.35 (-0.75 to 0.05) Q = 7.49, df = 4, I22 =
46.6%
Serotonin Norepinephrine Reuptake Inhibitors
Venlafaxine 8 Headaches/month Ozyalcin (2004) -2.0 (-4.0 to -0.06)
Serotonin Antagonist
Pizotifen 4 Headaches/month Arthur (1971) -0.51 (-1.07 to 0.05)
4 Headaches/month Ryan (1968) -0.36 (-0.86 to 0.15)
4 Pooled HA/month -0.42 (-0.80 to -0.05) Q = 0.16m df = 1, I2 =
0.0%
4 Headache index Carroll (1975) 0.18 (-0.87 to 1.23)
4 Headache index Lawrence (1977) -0.04 (-0.78 to 0.70)
4 Pooled SMD -0.15 (-0.47 to 0.17) Q = 6.40, df = 1, I2 = 0.0%
4 Overall Pooled SMD -0.30 (-0.62 to 0.02) Q = 6.40, df = 7, I2 = 0.0%
8 Headaches/month Kangasniemi (1979) -0.57 (-1.26 to 0.12)
8 Headaches/month Osterman (1977) -0.63 (-1.4 to 0.1)
8 Pooled HA/month -0.60 (-1.1 to -0.08) Q = 0.01, df = 1, I2 = 0.0%
8 Headache index Lawrence (1977) -0.56 (-1.32 to 0.20)
8 Overall Pooled SMD -0.48 (-0.85 to -0.12) Q = 1.37, df = 4, I2 = 0.0%
12 Headaches/month Bellavance (1990) -0.49 (-0.86 to -0.12)
12 Headaches/month Cleland (1997) -0.41 (-0.83 to 0.14)
12 Headaches/month Hughes (1971) -0.26 (-1.03 to 0.52)
12 Pooled HA/month -0.43 (-0.66 to -0.21) Q = 0.30, df = 2, I2 = 0.0%
12 Headache index Lawrence (1977) -0.56 (-1.32 to 0.20)
Overall Pooled SMD -0.44 (-0.69 to -0.20) Q = 0.48, df = 5, I2 = 0.0%
Tricyclic Antidepressants
Amitriptyline 4 Headache index Couch (2011) -0.34 (-0.62 to -0.05)
4 Headache index Zeigler (1987) -0.52 (-1.25 to 0.21)
4 Pooled SMD -0.57 (-0.92 to -0.23) Q = 0.08, df = 1, I2 = 0.0%
24 Headaches/month Gomersall (1973) -1.29 (-1.79 to -0.46)
24 Headache index Mathew (1981) -1.31 (-1.85 to -0.77)
24 Pooled SMD -1.2 (-1.7 to -0.82) Q = 0.35, df = 2, I2 = 0.0%
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blockers tested including acebutolol (n = 1), alprenolol (n = 1), atenolol (n = 3), bisoprolol
(n = 1), metoprolol (n = 4), oxprenolol (n = 1), pindolol (n = 2), propranolol (n = 19) and timo-
lol (n = 4).
Beta blockers no more effective than placebo included acebutolol, alprenolol, bisoprolol,
oxprenolol and pindolol (Table 5). Beta-blockers superior to placebo for episodic migraine
headaches (Table 5) included atenolol, metoprolol, propranolol (Fig 7) and timolol. Seven
studies found that propranolol reduced headache by 50% (Table 7). Neither atenolol (1 study)
nor propranolol (2 studies) were effective for chronic migraine (Table 6).
Calcium Channel Blockers. Calcium blockers headache trials tested cyclendelate (n = 1),
nicardipine (n = 1), nifedipine (n = 2), nimodipine (n = 5) and verapamil (n = 2). All studies
focused on episodic migraines (Table 2). Overall there were a total of 878 participants who
Table 5. (Continued)
Drug Time Point
(weeks)
Metric Study (Year) Pooled Mean Difference
(95% CI)
Heterogeneity
Clomipramine 4 Headaches/month Langohr (1985) 0.10 (-1.2 to 1.01)
4 Headaches/month Loldrup (1989) -0.51 (-0.81 to -0.20)
4 Headaches/month Noone (1980) -0.3 (-1.19 to 0.58)
4 Pooled SMD -0.46 (-0.74 to -0.18)
Doxepin 4 Headache index Morland (1979) -0.77 (-1.54 to 0.00) —
Opipramol 4 Headaches/month Jacobs (1972) -1.2 (-2.1 to -0.3)
12 Jacobs (1972) -1.3 (-2.5 to -0.12)
SMD: Standardized Mean Difference
doi:10.1371/journal.pone.0130733.t005
Fig 2. Alpha blockers compared to placebo for episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g002
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averaged 35 years in age (range 15–65) with 78% women. The average rate of withdrawals was
18%. Study duration averaged 11 weeks (range 4–20) with a mean of 52 participants (range 12–
192). No calcium channel blocker was more effective than placebo, including cyclendelate,
nicardipine, nifedipine, nimodipine and verapamil (Table 5). When the dihydropyridines
(nicardipine, nifedipine, nimodipine) were pooled, they were no better than placebo at reduc-
ing headaches.
Flunarizine. While classified as a calcium channel blocker, flunarizine has no influence on
blood pressure and its side effect profile suggests that its site of action is on cellular receptors
other than the calcium channel [231,232]. Flunarizine is not available in the United States.
There were 7 studies of episodic migraines, totaling 332 participants (Table 2). Studies averaged
47 participants, 36.4 years in age, 77% women, 12.5 weeks in duration and 9% dropouts. Four
studies reported headache frequency and three reported headache outcomes based on a head-
ache index. Flunarizine was superior to placebo at 8 and 12 weeks (Table 5, Fig 8), though not
at 4 weeks. Only a single trial reported the likelihood of a 50% reduction in headache with flu-
narizine with insignificant results (Table 7).
Selective Serotonin Reuptake Inhibitors (SSRI)/ Selective Norepinephrine Reuptake
inhibitors (SNRI). There were six SSRI and one SNRI placebo controlled trials, five focusing
on migraines and 1 on chronic daily headaches. There were a total of 335 participants who
Table 6. Placebo controlled comparisons of continuous outcomes among patients with chronic migraine headache ( 15 headaches/month).
Chronic Daily Headache
Fluoxetine 12 Headaches/month Saper (1994) -0.40 (-1.1 to 0.35) —
Gabapentin 8 Headaches/month Spira (2003) -2.7 (-5.2 to 0.28) —
Levetiracetam 82 Headaches/month Beran (2010) -3.6 (-7.7 to 0.56) —
Chronic Migraines (15 or more headaches/month)
Atenolol 6 Headaches/month Stensrud (1980) 0.32 (-0.73 to 1.38) —
Propranolol 8 Headaches/month Palferman (1988) -0.70 (-1.3 to -0.09)
6 Headaches/month Stensrud (1980) 0.24 (-0.82 to 1.29)
Pooled SMD -0.34 (-1.23 to 0.56) Q = 0.13, df = 2, I2 = 56.1%
Tizanidine 4 Headaches/month Saper (2002) -1.1 (—2.4 to 0.16) —
8 Headaches/month Saper (2002) -1.0 (-2.3 to 0.30) —
12 Headaches/month Saper (2002) -0.50 (-1.6 to 0.62) —
Topiramate 4 Headaches/month Diener (2007) -4.9 (-7.7 to -2.1)
4 Headaches/month Mei (2006) -9.2 (-15.7 to -2.7)
4 Headaches/month Silvestrini (2003) -5.0 (-9.2 to -0.81)
4 Pooled (HA/Month) -5.4 (-7.6 to -3.2) Q = 0.34, df = 2, I2 = 0.0%
8 Headaches/month Diener (2007) -3.1 (-5.9 to -0.29)
8 Headaches/month Mei (2006) -12.7 (-10.2 to -6.2)
8 Headaches/month Silvestrini (2003) -12.5 (-17.1 to -7.9)
Pooled (HA/Month): -9.1 (-16.3 to -1.9) Q = 9.33, df = 2, I2 = 78.6%
12 Headaches/month Diener (2007) -6.0 (-8.8 to -3.2)
12 Headaches/month Mei (2006) -12.2 (-18.7 to -5.7)
Pooled (HA/Month): -8.4 (-14.3 to -2.5) Q = 0.81, df = 1, I2 = 0.0%
16 Diener (2007) -7.6 (-10.4 to -4.8)
Valproate 4 Headaches/month Yurekli (2008) -12.6 (-17.9 to -7.3)
12 Headaches/month Sarchelli (2014) -4.3 (-7.1 to -1.5)
12 Headaches/month Yurekli (2008) -14.3 (-19.5 to -9.1)
12 Pooled (HA/Month): -10.9 (-18.5 to -3.4) Q = 26.2, df = 1, I2 = 92.4%
doi:10.1371/journal.pone.0130733.t006
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averaged 36.9 years in age (range 18–65) with 81% women (Table 2). The average rate of with-
drawals was 25% (range 0–41%). Study duration averaged 12 weeks (range 8–20) with a mean
of 56 participants (range 27–111). Specific drugs tested include three SSRIs (femoxitine, n = 1,
fluoxetine, n = 4 and sertraline, n = 1), and one SNRI (venlaxafine, n = 1). Four of the SSRI tri-
als reported a headache index. One SSRI trial and the SNRI trial reported frequency of head-
aches per month.
For migraine headaches, two SSRI’s, femoxitine and sertraline, were no more effective than
placebo while fluoxetine was effective at 12 weeks (Fig 9). A single trial of venlafaxine found
benefit at 8 weeks (Table 5). For chronic daily headache a single trial of fluoxetine found no
benefit (Table 6). Only a single trial (fluoxetine) investigated the likelihood of reducing head-
aches by at least 50% and found no benefit over placebo (Table 7).
Serotonin Antagonists. Pizotifen is a serotonin antagonist, commonly used for migraine
treatment in the 1970’s and 80’s. There were 9 placebo controlled trials with a total of 600 par-
ticipants and all focused on episodic migraine headaches (Table 2). The average rate of with-
drawals was 20% (range 0–48). Study duration averaged 8 weeks (range 4–12) with a mean of
67 participants (range 26–176). Two studies reported a headache index, the other 7 headache
frequency. Pizotifen was superior to placebo at all time points (Fig 10, Table 5). No trials
reported on the likelihood of achieving at least 50% improvement in headaches.
Tricyclic Antidepressants (TCA)
There were 8 trials comparing a TCA to placebo, one focusing on chronic daily headaches, the
remainder on episodic migraine headaches. There were a total of 1570 participants. The aver-
age rate of withdrawals was 37% (range 20–52%). Study duration averaged 10 weeks (range
4–24) with a mean of 143 participants (range 10–554). Tricyclic’s studied included
Fig 3. ACE and ARBs compared to placebo for episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g003
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Table 7. Placebo controlled comparisons of >50% improvement in episodic migraine headaches (<15migraines/month).
Drug Time Point (weeks) Study (Year) RR (95% CI) Heterogeneity
Angiotensin Converting Enzyme Inhibitors
Captopril 8 Sonbolestan (2013) 5.6 (1.4–21.9)
Lisinopril 12 Schrader (2012) 0.82 (0.46–1.5)
Angiotensin Receptor Blockers
Candesartan 12 Tronvik (2003) 18.0 (2.5–130.4)
Telmisartan 12 Diemer (2009) 1.6 (0.85–3.0)
12 Pooled RR 4.4 (0.43–46.2) Q = 5.2, df = 1 I2 = 80.8%
Anticonvulsants
Acetazolamide 12 Vahedi (2002) 0.92 (0.42–2.0)
Carisbamate 12 Cady (2009) 0.75 (0.58–0.98)
Lamotrigine 4 Gupta (2006) 1.4 (0.86–2.2)
12 Steiner (1997) 0.20 (-0.36 to 0.76)
Levetiracetam 12 Verma (2003) 1.4 (0.86–2.4)
Oxcarbazepine 15 Silberstein (2008) 0.90 (0.59–1.4)
Topiramate 4 Edwards (2003) 4.2 (1.3–13.7)
4 Gupta (2006) 2.1 (1.3–3.2)
4 Pooled RR: 2.4 (1.3–4.2) Q = 11.27, df = 1, I2 = 21.0%
12 Silberstein (2006) 1.2 (0.8–1.7)
16 Silberstein (2004) 2.1 (1.6–2.7)
16 Silberstein (2009) 1.3 (0.9–2.0)
16 Pooled RR: 1.9 (1.4–2.5) Q = 6.4, df = 1, I2 = 52.9%
26 Brandes (2004) 1.7 (1.3–2.2)
26 Diener (2004) 1.6 (1.1–2.4)
26 Pooled RR: 1.8 (1.5–2.2) Q = 1.72, df = 1, I2 = 0.0%
26 Freitag (2002) 1.2 (0.8–1.9)
Valproate 12 Jensen (1994) 2.8 (1.3–6.3)
12 Klapper (1997) 2.3 (1.6–3.3)
12 Mathew (1995) 3.6 (1.5–8.4)
12 Pooled RR 2.1 (1.5–3.0) Q = 9.1, df = 3, I2 = 45.1%
Beta-blockers
Propranolol 4 Stensrud (1976) 1.25 (0.55–2.8)
8 Pita (1977) 17.0 (1.0–281.9)
8 Zeigler (1993) 2.5 (0.65–9.7)
8 Pooled RR: 4.3 (0.79–23.6) Q = 1.45, df = 1, I2 = 31.1%
12 Telt-Hansen (1984) 2.0 (1.2–2.8)
12 Weber (1972) 7.5 (1.9–28.4)
12 Wideroe (1974) 2.2 (1.4–3.4)
12 Pooled RR: 2.1 (1.6–2.9) Q = 4.2, df = 2, I2 = 52.2%
24 Diener (1996) 1.4 (0.9–2.2)
26 Diener (2004) 2.0 (1.4–2.9)
Metoprolol 4 Langohr (1985) 1.2 (0.86–1.5)
Timolol 8 Stellar (1984) 1.6 (1.1–2.4)
12 Tfelt-Hansen (1984) 1.9 (1.4–2.5)
Calcium Channel Blockers
Cinnarizine 4 Togha (2007) 0.98 (0.74–1.3)
Cyclendalate 24 Diener (1996) 1.3 (0.8–2.1)
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Table 7. (Continued)
Drug Time Point (weeks) Study (Year) RR (95% CI) Heterogeneity
Flunarizine 12 Thomas (1991) 2.5 (0.6–10.9)
16 Bunoso (1998) 0.99 (0.72–1.4)
16 Diener (2002) 1.0 (0.88–1.2)
16 Pooled RR: 1.02 (00.91–1.1) Q = 1.6, df = 1, I2 = 82.4%
Nifedipine 24 Albers (1989) 0.45 (0.21–0.95)
Fluoxetine 4 Singh (2002) 4.5 (1.1–18.8)
12 Saper (1994) 1.0 (0.57–1.8)
Tricyclic Antidepressants
Amitriptyline 4 Couch (1976) 2.2 (1.0–4.8)
4 Couch (1979) 1.60 (1.0–2.5)
4 Pooled RR: 1.7 (1.2–2.6) Q = 0.54,df = 1, I2 = 0.0%
8 Nelson (1998) 2.22 (1.3–3.9)
8 Zeigler (1993) 0.83 (0.43–1.6)
8 Pooled RR: 1.1 (0.6–2.0) Q = 0.64,df = 1, I2 = 3.0%
12 Canepari (1985)) 1.60 (0.31–3.1)
26 Dodick (2009) 0.82 (0.61–1.1)
Clomipramine 4 Langohr (1985) 0.94 (0.53–1.7)
Tetracyclic
Maprotiline 12 Amelin (2000) 0.76 (0.32–1.8)
doi:10.1371/journal.pone.0130733.t007
Fig 4. Topiramate compared to placebo for episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g004
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Fig 5. Valproate compared to placebo for episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g005
Fig 6. Dose response relationship of headache to topiramate dose.
doi:10.1371/journal.pone.0130733.g006
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Fig 7. Propranolol compared to placebo for episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g007
Fig 8. Flunarizine compared to placebo for episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g008
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Fig 9. SSRI/SNRIs compared to placebo for episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g009
Fig 10. Pizotifen compared to placebo for episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g010
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Fig 11. TCAs compared to placebo for episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g011
Fig 12. Amitriptyline compared to placebo for migraine headaches.
doi:10.1371/journal.pone.0130733.g012
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Table 8. Characteristics of comparative effectiveness trials.
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Comparison
Drugs
Headache
Measure
Study
design
(washout,
weeks)
Duration,
weeks
Sample
size
Drop-
outs
Age Female
Episodic (<15 headaches/month)
Afshari [180], 2012,
Iran
Episodic 7.6 Topiramate (50) v.
Valproate (400)
Frequency Parallel 12 76 26% 30.7 79%
Albers [181], 1989,
USA
Episodic 4.3 Propranolol (180)
v. Nifedipine (90)
Frequency Parallel 24 40 50% 35.2 85%
Amelin[182], 2000,
Russia
Episodic 4.3 Amitriptyline (25)
v. Fluoxetine (20)
Frequency Parallel 12 46 23% 36 95%
Andersson [183],
1973, Denmark
Episodic 2.3 Pizotifen (2) v.
Methysergide (4)
Frequency Crossover
(0)
12 73 33% ns 84%
Andersson [242],
1981, Denmark
Episodic 5.7 Propranolol (160)
vs. Femoxetine
(400)
Frequency Crossover
(0)
8 49 24% 38 69%
Ashtari [185], 2008,
Iran
Episodic 5.95 Propranolol (80) v.
Topiramate (50)
Frequency Parallel 8 62 3% 30.8 82%
Bank [186], 1994,
Hungary
Episodic ns Amitriptyline (25)
v. Fluvoxamine
(50)
Frequency Parallel 12 44 23% 34 80%
Bellavance [163],
1990, Canada
Episodic 6.7 Pizotifen (1.5) v.
Naproxen (1100)
Frequency Parallel 12 176 14% 32.5 79%
Bordini [190], 1997,
Brazil
Episodic 3.9 Propranolol (60) v.
Flunarizine (10)
Headache
Index
Parallel 24 52 13% ns 91%
Bostani [191], 2013,
Iran
Episodic 6.1 Valproate (400) v.
Cinnarizine (50)
Frequency Parallel 12 132 21% 32.2 68%
Bulut [192], 2004,
Turkey
Episodic 3.5 Amitriptyline (75) v
Venlafaxine (150)
Frequency Crossover
(4)
12 52 32% 31.9 85%
Cady [193], 2011,
USA
Episodic 5.9 Topiramate (100)
v. frovatriptan (5-
with aura)
Frequency Parallel 8 55 20% 37.5 78%
Cerbo [194], 1986,
Italy
Episodic ns Flunarizine (15) v.
Pizotofen (1.5)
Frequency Crossover
(2)
8 27 33% ns ns
Diener [106], 1996,
Germany
Episodic 4 Propranolol(120) v
Cyclendalate
(1200) v. Placebo
Duration
(hours)
Parallel 12 214 17% 39 78%
Diener [195], 2002,
EU
Episodic 3 Propranolol (160)
v. Flunarizine (5)
v. Flunarizine (10)
Frequency Parallel 16 783 18% 37 81%
Diener [73], 2004, EU Episodic 3.9 Propranolol (160)
v. Topiramate
(100) v. Placebo
Frequency Parallel 26 568 37% 40.8 80%
Dodick [196], 2009,
USA
Episodic 6.9 Amitriptyline (100)
v. Topiramate
(100)
Frequency Parallel 26 331 43% 38.8 85%
Formisano [198],
1991, Italy
Episodic 4 Propranolol (120)
v. Nimodipine
(120)
Frequency Parallel 12 22 14% 39.2 55%
Forssman [199],
1972, Sweden
Episodic 6.8 Pizotifen (3) v.
methysergide (3)
Frequency Crossover
(0)
10 22 23% 40.3 53%
Gawel [200], 1992,
Canada
Episodic 4.7 Propranolol (160)
v. Flunarizine (10)
Frequency Parallel 16 94 19% 35.7 90%
Gerber [201], 1991,
Germany
Episodic 3.5 Propranolol (120)
v. Metoprolol (200)
v. Nifedipine (20)
Frequency Parallel 12 58 28% 42.4 81%
(Continued)
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Table 8. (Continued)
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Comparison
Drugs
Headache
Measure
Study
design
(washout,
weeks)
Duration,
weeks
Sample
size
Drop-
outs
Age Female
Gupta [202], 2007,
India
Episodic 6.9 Topiramate (50) v.
Lamotrigine (50)
Frequency Crossover
(1)
4 57 7% 29.4 78%
Havanka-Kannianen
[141], 1987, Finland
Episodic 5.2 Nimodipine
(120mg) v.
Pizotifen (1.5) v.
Placebo
Frequency Crossover
(4)
12 43 14% 37.6 79%
Hübbe [35], 1973,
Denmark
Episodic ns Pizotifen (1.5) v.
Prochlorperazine
(15) v. Placebo
Frequency Crossover
(0)
8 50 32% 35 71%
Kalita [204], 2013,
India
Episodic 10.8 Amitriptyline (50)
v. Valproate
(1000)
Frequency Parallel 24 300 0% 32 80
Kangasniemi [167],
1979, Finland
Episodic 6.2 Pizotifen (1.5) v.
Divascan (5) v.
Placebo
Frequency Crossover
(4)
7 50 13% 37 71%
Kangasniemi [205],
1983, Finland
Episodic 7.2 Propranolol (160)
v. Femoxitine
(400)
Frequency Crossover
(1)
16 29 17% 37 86%
Kangasniemi [116],
1984, Finland
Episodic 5.3 Propranolol (240)
v. Metoprolol (200)
Frequency Crossover
(3)
8 36 8% 33.8 89%
Kaniecki [206], 1997,
USA
Episodic 4.4 Dvalproex (1500)
v. Propranolol
(240) v. Placebo
Headache
Index
Parallel 12 37 14% ns 81%
Kass [178], 1980,
Norway
Episodic ns Propranolol (40) v.
Clonidine (0.05)
Frequency Crossover
(0)
16 23 9% 39.7 70%
Keskinbora [207],
2008, Turkey
Episodic 6.1 Amitriptyline (150)
v Topiramate
(200)
Frequency Parallel 12 63 16% 37 67%
Krymchantowski
[209], 2012, Brazil
Episodic 7 Topiramate (100)
v. Nortriptyline
(30) v.
combination
Frequency Parallel 10 38 13% 36 85%
Langohr [175], 1985,
Germany
Episodic ns Clomipramine
(100) v. Metoprolol
(100) v. Placebo
Frequency Crossover
(4)
4 36 43% 44 67%
Louis [210], 1982,
Belgium/Netherlands
Episodic 2.2 Flunarizine (10) v.
Pizotifen (3)
Frequency Crossover
(0)
16 75 ns 37 57%
Louis [179], 1985,
Belgium
Episodic ns Metoprolol (100) v.
Clonidine (0.1)
Frequency Crossover
(2)
8 33 6% 33.5 81%
Lucking [211], 1988,
Germany
Episodic 6 Propranolol (120)
v Flunarizine (10)
Frequency Parallel 16 434 23% 42 82%
Ludin [212], 1989.
Switzerland
Episodic 6.3 Propranolol (120)
v. Flunarizine (10)
Frequency Parallel 16 87 17% 42 74%
Luo [213], 2012,
China
Episodic 4.5 Topiramate () v.
Flunarizine (5) v.
combination
Frequency Parallel 48 150 16% 43 71%
Mathew [118], 1981,
USA
Unclear ns Amitriptyline (75) v
Propranolol (160)
v. Placebo
Frequency Parallel 24 554 22% 38 95%
Mitsikostas [214],
1997, Greece
Episodic 4.6 Valproate (1000)
v. Flunarizine (10)
Frequency Parallel 8 44 ns 35.4 73%
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Meta-Analysis of Prophylactic Treatment of Migraine Headaches
PLOS ONE | DOI:10.1371/journal.pone.0130733 July 14, 2015 38 / 60
Table 8. (Continued)
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Comparison
Drugs
Headache
Measure
Study
design
(washout,
weeks)
Duration,
weeks
Sample
size
Drop-
outs
Age Female
Mohammadianinejad
[215], 2011, Iran
Episodic 7.4 Topiramate (100)
v. Zonisamide
(200)
Frequency Parallel 12 80 6% 34.3 69%
Olerud [216], 1986,
Sweden
Episodic 4.6 Propranolol (80) v.
Nadolol (80)
Frequency Parallel 12 28 ns ns ns
Olsson [217], 1984,
Sweden
Episodic 5.4 Propranolol (80) v.
Metoprolol (100)
Frequency Crossover
(4)
8 56 5% 39 73%
Osterman [169],
1977, Sweden
Episodic Pizotifen (0.5) v.
Divascan v.
Placebo
Frequency Crossover
(2)
8 30 10% 37 70%
Presthus [218], 1971,
Norway
Episodic Pizotifen (1.5) v.
Methysergide (3)
Frequency Crossover
(1)
21 21 10% 42.7 67%
Rampello [219],
2004, Italy
Episodic Amitriptyline (50)
v. Citalopram (20)
Frequency Parallel 16 88 0% 39 63%
Rascol [220], 1986,
France
Episodic 4.3 Flunarizine (10) v.
Pizotifen (2)
Frequency Parallel 16 35 9% 38 71%
Ryan [170], 1968,
USA
Episodic 8.5 Pizotifen (4) v.
Methysergide (4)
v. Placebo
Frequency Crossover
(0)
4 62 ns ns ns
Ryan [221], 1984,
USA
Episodic 6.5 Propranolol (160)
v. Nadolol (80) v.
Nadolol (160)
Frequency Parallel 12 48 6% ns 73%
Scholz (188), 1987,
Germany
Episodic Propranolol (80) v.
Metoprolol (100) v.
Nifedipine (40) v.
Flunarizine (10)
Frequency Parallel 12 109 24% 40.4 83%
Shaygannejad [223],
2006, Iran
Episodic 5.4 Topiramate (50) v.
Valproate (500)
Crossover
(8)
Parallel 8 64 0% 34.1 60%
Shimell [224], 1990,
S Africa
Episodic 4.7 Propranolol (240)
v. Flunarizine (10)
Frequency Parallel 16 57 2% 34 70%
Sorensen [225],
1991, Denmark
Episodic 4.3 Metoprolol (200) v.
Flunarizine (10)
Frequency Parallel 20 149 15% 42 79%
Stovner, 2013,
Norway
Episodic Candesartan (16),
Propranolol (160)
Frequency Crossover 12 61 15% 37 82%
Sudilovsky [226],
1987, USA
Episodic 5.3 Nadolol (80) v.
Nadolol (160)
Frequency Parallel 8 168 20% ns ns
Stensrud (107), 1980,
Norway
Episodic 5.6 Propranolol (160)
v. Atenolol (100) v.
Placebo
Crossover
(1)
Crossover
(1)
Parallel 6 7 20% 25 69%
Tarasova [227], 2008,
Russia
Amitriptyline () v.
Fluvoxamine ()
Frequency Parallel
Togha [228], 2008,
Iran
Episodic 7.2 Valproate (600) v.
Cinnarizine (75)
Frequency Parallel 12 125 37% 34.1 80%
Vilming [229], 1985,
Sweden/Norway
Episodic 6 Metoprolol (100) v.
Pizotifen (1.5)
Frequency Crossover
(0)
4 35 ns 37.6 83%
Zain [230], 2013,
Pakistan
Episodic 11.32 Topiramate (200)
v. Gabapentin
(1200)
Frequency Parallel 12 80 0% 32 80%
Ziegler [136], 1987,
USA
Episodic Ns Amitriptyline (150)
v. Propranolol
(240) v. Placebo
Frequency Crossover
(4)
4 30 44% 38 73%
(Continued)
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amitriptyline (n = 5), clomipramine (n = 2) doxepin (n = 1) and opipramol (n = 1). Four trials
reported headache frequency and 4 used a headache index as their outcome measure.
For episodic migraines, amitriptyline, clomipramine and doxepin were better than placebo
(Table 5, Fig 11), while opipramol (Table 5) was ineffective. Amitriptyline was the best studied
TCA (Fig 12), though two of the studies were only 4 weeks in duration. Amitriptyline was
more likely than placebo to produce a 50% reduction in episodic migraine headaches (Table 7).
A single trial found amitriptyline ineffective for chronic daily headaches (Table 6).
Comparative Effective Trials
There were a total of 60 trials with comparisons between different prophylactic drugs for head-
aches, 55 including subjects with episodic headaches, five with chronic migraine headaches.
Not all prophylactic drugs were directly compared with each other (Table 8). Quality ratings
for these trials are given in Table 9. Drugs that were frequently compared to other active drugs
include amitriptyline, metoprolol, pizotifen, propranolol, topiramate and valproate. There
were few differences in effectiveness between the different drugs. Amitriptyline was no more
effective than SSRIs, venlafaxine, topiramate or propranolol. Among beta-blockers, metoprolol
was superior to clonidine, flunarizine and nifedipine and propranolol was better than femoxi-
tine. Propranolol was equivalent to metoprolol, atenolol, nadolol as well as to flunarizine and
topiramate (Table 10). Among the anticonvulsants, topiramate was equivalent to flunarizine,
lamotrigine and to valproate and valproate was equivalent to flunarizine. For chronic
migraines, popranolol was better than nortriptyline.
Network Meta-analysis
Candidate drugs for the network meta-analysis were those drugs found effective for treatment
of episodic migraine headaches with at least 3 randomized clinical trials. These included eleven
different drugs used in prophylaxis of episodic migraine headaches (Fig 13). Indirect compari-
sons of these eleven individual drugs using meta-regression suggested that amitriptyline was
more effective than several of the other drugs including candesartan (p = 0.04), fluoxetine
Table 8. (Continued)
Author, year,
Country
Migraine
Type
Baseline
Headache
Frequency
Comparison
Drugs
Headache
Measure
Study
design
(washout,
weeks)
Duration,
weeks
Sample
size
Drop-
outs
Age Female
Chronic Migraine (15 headaches/month)
Bartolini [187], 2005,
Italy
Chronic
Migraine
26.6 Topiramate (75) v.
Valproate (750)
Frequency Parallel 8 49 14% 41.8 70%
Behan [188], 1986,
UK
Chronic
Migraine
15 Pizotifen (1.5) v.
Naproxen (1100)
Frequency Parallel 12 74 45% ns 82%
Domingues [197],
2009, Brazil
Chronic
Migraine
16.7 Nortriptyline (40)
v. Propranolol (80)
Frequency Parallel 6 76 42% ns ns
Krymchantowski
[208], 2002, Brazil
Chronic
(transformed)
migraine
25.7 Amitriptyline (40)
v. Amitriptyline
(40)+Fluoxetine
(40)
Frequency Parallel 9 39 44% 36.4 67%
Stensrud (107), 1980,
Norway
Chronic 22 Propranolol (160)
v. Atenolol (100) v.
Placebo
Crossover
(1)
Crossover
(1)
Parallel 6 28 20% 25 69%
doi:10.1371/journal.pone.0130733.t008
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Table 9. Quality Assessment among comparative effectiveness trials.
Cochrane Risk of Bias
Study Jadad
Score
(0–8)
Intention
to Treat
Adequate
sequence
generation
Adequate
concealed
allocation
Adequate
Blinding
Incomplete
outcome
data
addressed
Free of
selective
outcome
reporting
Free of
“other”
bias
Industry
sponsored
EPISODIC MIGRAINES
Afshari [180], 2012,
Topiramate/valoproate
4 No Unclear Unclear Unclear No Unclear Unclear No
Albers [181], 1989,
Propranolol/Nifedipine
5 No Yes Yes No No No No Yes
Amelin[182], 2000,
Amitriptyline/Fluoxetine
4 No No Unclear No No Unclear Yes No
Andersson [183], 1973,
Pizotifen/Methysergide
4 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Andersson [242], 1981,
Propranolol/Femoxitine
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Ashtari [185], 2008,
Propranolol/Topiramate
5 No Yes Yes Unclear No Yes Unclear Unclear
Bank [186], 1994,
Amitriptyiline/
Fluvoxamine
4 No Unclear Unclear Unclear No Unclear Yes Unclear
Bartolini [187], 2005,
Topiramate/Valproate
3 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Behan [188], 1986,
Pizotifen/Naproxen
2 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Bellavance [163], 1990,
Pizotifen/Naproxen
3 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Bordini [190], 1997,
Propranolol/Flunarizine
4 No Unclear Unclear Yes No No No Unclear
Bulut [192], 2004,
Amitriptyline/Venlafaxine
6 No Unclear Unclear Yes No Unclear Yes Yes
Cady [193], 2011,
Topiramate/Froyatriptan
3 Unclear Unclear No Unclear Unclear Unclear Yes
Cerbo [194], 1986,
Flunarizine/Pizotifen
6 Yes Unclear Unclear Yes Unclear Unclear Unclear Unclear
Diener [106], 1996,
Propranolol/
Cyclendalate/Placebo
4 Yes Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Diener [195], 2002,
Propranolol/Flunarizine
8 No Yes Yes Yes No Unclear Unclear Yes
Diener [73], 2004,
Propranolol/Topiramate/
Placebo
8 Yes Unclear Unclear Unclear Yes Yes Unclear Yes
Dodick [196], 2009,
Amitriptyline/Topiramate
8 No Yes Yes Yes Yes Yes Yes Yes
Domingues [197], 2009,
Nortriptyline/Propranolol
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Formisano [198], 1991,
Propranolol/Nimodipine
4 No Unclear Unclear No No No No Unclear
Forssman [199], 1972,
Pizotifen/Methyergide
5 No Unclear Unclear t Unclear Unclear Unclear Unclear
Gawel [200], 1992,
Propranolol/Flunarizine
4 No Unclear Unclear Unclear No No Unclear Yes
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Table 9. (Continued)
Cochrane Risk of Bias
Study Jadad
Score
(0–8)
Intention
to Treat
Adequate
sequence
generation
Adequate
concealed
allocation
Adequate
Blinding
Incomplete
outcome
data
addressed
Free of
selective
outcome
reporting
Free of
“other”
bias
Industry
sponsored
Gerber [201], 1991,
Propranolol/Metoprolol/
Nifedipine
3 No Unclear Unclear Unclear No Yes Unclear Unclear
Gupta, 2007, Lamotrigin/
Topiramate/Placebo
8 Yes Yes Yes Yes Unclear Unclear Unclear Yes
Havanka-Kannianen
[141], 1987, Nimodipine/
Pizotifen/Placebo
3 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Hübbe [35], 1973,
Pizotifen/
Prochlorperazine/
Placebo
3 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Kangasniemi [167],
1979, Pizotifen/
Divascan/Placebo
6 No 50 (32%) 37 (71%) Unclear Unclear Unclear Unclear Unclear
Kangasniemi [205],
1983, Propranolol/
Femoxitine
2 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Kangasniemi [116],
1984, Propranolol/
Femoxitine/Placebo
2 No 29 (17%) 37 (86%) Unclear Unclear Unclear Unclear Unclear
Kaniecki [206], 1997,
Divalproex/Propranolol/
Placebo
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Kaas, 1980, Norway,
Propranolol/Clonidine
4 Unclear Unclear Unclear Unclear Unclear Unclear Unclear No
Keskinbora [207], 2008,
Amitiprytilne/Topiramate
6 No Unclear Yes Yes No Yes Yes Unclear
Krymchantowski [208],
2002, Amitriptyline/
Amitriptyline+Fluoxetine
5 No Unclear Unclear Yes Unclear Unclear Unclear No
Krymchantowski [209],
2012, Topiramate/
Nortiptyline/Combination
8 No Yes Yes Yes Unclear Unclear Unclear Unclear
Langohr [175], 1985,
Clomipramine/
Metoprolol/Placebo
4 No Unclear Unclear Unclear No No Yes Yes
Louis [210], 1982,
Flunarizine/Pizotifen
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Louis, 1985, Metoprolol/
Clonidine
4 Unclear Unclear Unclear Unclear Unclear Unclear Unclear No
Lucking [211], 1988,
Propranolol/Flunarizine
4 No Unclear Unclear Unclear Unclear Unclear Unclear Yes
Ludin [212], 1989,
Propranolol/Flunarizine
3 Yes Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Luo [213], 2012,
Topiramate/Flunarizine/
Combination
2 Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Mathew [118], 1981,
Amitriptyline/Propranolol/
Placebo
2 No Unclear Unclear No No No Yes Unclear
Mitsikostas [214], 1997,
Valproate/Flunarizine
4 No Unclear Unclear No Unclear Unclear Unclear Unclear
(Continued)
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(p = 0.03), propranolol (p = 0.009), topiramate (p = 0.005) and valproate (p = 0.009, Fig 12),
and no different than atenolol (p = 0.20), flunarizine (p = 0.06), clomipramine (p = 0.15) or
metoprolol (p = 0.15). The network meta-analysis found no differences between the other
drugs in the relative effectiveness in the prophylaxis against migraine headaches. (p = 0.21).
Table 9. (Continued)
Cochrane Risk of Bias
Study Jadad
Score
(0–8)
Intention
to Treat
Adequate
sequence
generation
Adequate
concealed
allocation
Adequate
Blinding
Incomplete
outcome
data
addressed
Free of
selective
outcome
reporting
Free of
“other”
bias
Industry
sponsored
Mohammadianinejad
[215], 2011, Topiramate/
Zonisamide
6 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Olerud [216], 1986,
Propranolol/Nadolol
4 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Olsson [217], 1984,
Propranolol/Metoprolol
6 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Osterman [169], 1977,
Pizotifen/Divascan/
Placebo
5 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Presthus [218], 1971,
Pizotifen/Methysergide
1 No Unclear Unclear Unclear Unclear Unclear Unclear
Rampello [219], 2004,
Amitriptyline/Citalopram
4 Yes Unclear Unclear No Yes Unclear Yes Unclear
Rascol [220], 1986,
Flunarizine/Pizotifen
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Ryan [170], 1968,
Pizotifen/Methysergide/
Placebo
5 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Ryan [221], 1984,
Propranolol/Nadolol
2 Yes Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Scholz (188), 1987,
Propranolol/Metoprolol/
Nifedipine/Flunarizine
3 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Shaygannejad [223],
2006, Topiramate/
Valproate
4 Yes Unclear Unclear Unclear Unclear Yes Unclear Unclear
Shimell [224], 1990,
Propranolol/Flunarizine
6 Yes Unclear Unclear Yes No No Unclear Yes
Sorensen [225], 1991,
Metoprolol/Flunarizine
6 No Unclear Unclear Yes Yes Yes Unclear Unclear
Stensrud (107), 1980,
Propranolol/Atenolol
7 No Unclear Unclear Yes Unclear Unclear Unclear Yes
Sudilovsky [226], 1987,
Nadolol (two doses)
5 No Unclear Unclear Yes Unclear Unclear Unclear Unclear
Togha [228], 2008,
Valproate/Cinnarizine
8 Yes Yes Yes Yes Yes Yes Yes Unclear
Vilming [229], 1985,
Metoprolol/Pizotifen
4 No Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Ziegler [136], 1987,
Amitriptyline/Propranolol/
Placebo
3 No Unclear Unclear Unclear No Unclear Yes No
doi:10.1371/journal.pone.0130733.t009
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Table 10. Comparative Effectiveness Trial Outcomes.
Drug 1 Drug 2 Study (year) Standardized Mean Difference (95% CI)δ Heterogeneity
Episodic Migraines (<14 headaches/month)
Amitriptyline Fluoxetine Amelin (2000) -0.14 (-0.85 to 0.58)
Amitriptyline Fluvoxamine Bank (1994) 0.37 (-0.20 to 0.93)
Amitriptyline SSRI Pooled SMD 0.17 (-0.32 to 0.65) Q = 1.15, df = 1. I2 = 12.9%
Amitriptyline Maprotiline Amelin (2000) -0.15 (-0.87 to 0.57)
Amitriptyline Topiramate Dodick (2009) -0.08 (-0.30 to 0.13)
Amitriptyline Topiramate Keskinbora (2008) 0.31 (-0.30 to 0.92)
Amitriptyline Topiramate Pooled SMD 0.01 (-0.32 to 0.33) Q = 1.41, df = 1, I2 = 29.2%
Amitriptyline Venlafaxine Bulut (2004) -0.12 (-0.51 to 0.26)
Amitriptyline Propranolol Ziegler (1987) 0.17 (-0.55 to 0.88)
Flunarizine Flunarizine + Topiramate Luo (2012) 0.21 (-0.23 to 0.64)
Metoprolol Flunarizine Scholz (1981) -0.83 (-1.65 to -0.01)
Metoprolol Flunarizine Sorensen (1991) -0.35 (-0.69 to -0.02)
Metoprolol Flunarizine Pooled SMD -0.43 (-0.77 to -0.10) Q = 1.06, df = 1. I2 = 5.8%
Metoprolol Nifedipine Gerber (1991) -0.66 (-1.31 to -0.01)
Metoprolol Nifedipine Scholz (1987) -0.92 (-1.78 to -0.06)
Metoprolol Nifedipine Pooled SMD -0.75 (-1.27 to -0.24) Q = 0.24, df = 1, I2 = 0.0%).
Metoprolol Clomipramine Langohr (1985) -1.4 (-2.8 to 0.03)
Metoprolol Clonidine Louis (1985) -0.54 (-1.07 to -0.01)
Metoprolol Pizotifen Vliming (1985) -0.43 (-1.15 to 0.30)
Pizotifen Flunarizine Cerbo (1986) 0.19 (-0.74 to 1.12)
Pizotifen Flunarizine Louis (1982) 0.14 (-0.34 to 0.63)
Pizotifen Flunarizine Rascol (1986) 0.40 (-0.29 to 1.08)
Pizotifen Flunarizine Pooled SMD 0.22 (-0.14 to 0.59) Q = 0.36, df = 2, I2 = 0.0%
Pizotifen Divascan Osterman (1977) -0.38 (-1.14 to 0.39) —
Pizotifen Methysergide Andersson (1973) -0.17 (-0.74 to 0.40)
Pizotifen Methysergide Forsmann (1972) 0.10 (-0.66 to 0.85)
Pizotifen Methysergide Presthus (1971) 0.24 (-0.64 to 1.12)
Pizotifen Methysergide Ryan (1968) -0.13 (-0.63 to 0.37)
Pizotifen Methysergide Pooled SMD -0.06 (-0.37 to 0.26) Q = 0.83, df = 3, I2 = 0.0%
Pizotifen Nimodipine Havanka (1987) 0.11 (-0.59 to 0.71) —
Pizotifen Naproxen Bellavance (1990) 0.10 (-0.27 to 0.46) —
Pizotifen Prochloperazine Hübbe (1973) -0.33 (-0.96 to 0.29) —
Propranolol Atenolol Stensrud (1980) 0.02 (-0.84 to 0.88) —
Propranolol Clonidine Kaas (1980) 0.03 (-0.58 to 0.63) —
Propranolol Cyclandelate Diemer (1996) -0.07 (-0.38 to 0.24) —
Propranolol Femoxetine Andersson (1981) -0.40 (-1.05 to 0.25)
Propranolol Femoxetine Kangasniemi (1983) -2.03 (-2.66 to -1.39)
Propranolol Femoxetine Pooled SMD -1.21 (-2.8 to -0.37) Q = 17.35, df = 1, I2 = 88.5%
Propranolol Flunarizine Bordini (1997) -0.32 (-0.40 to 1.05)
Propranolol Flunarizine Diener (2002) -0.38 (-0.52 to -0.24)
Propranolol Flunarizine Gawel (1992) 0.58 (0.12 to 1.04)
Propranolol Flunarizine Lucking (1988) -0.20 (-0.67 to 0.27)
Propranolol Flunarizine Ludin (1989) -0.21 (-0.73 to 0.30)
Propranolol Flunarizine Scholz (1987) -0.37 (-1.16 to 0.43)
Propranolol Flunarizine Shimell (1990) -0.02 (-0.55 to 0.50)
Propranolol Flunarizine Pooled SMD -0.04 (-0.34 to 0.26) Q = 20.62, df = 6, I2 = 70.9%
(Continued)
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Placebo effect
There were 78 studies that provided baseline headache frequency that included 4579 episodic
migraine sufferers who were randomized to placebo. On average, patients randomized to the
placebo group experienced 5.3 (95% CI: 4.9–5.8) headaches/month at baseline. Patients receiv-
ing placebos experienced a significant decline in headache frequency by 4 weeks, an effect that
persisted through 12 weeks. By weeks 16, 20 and 24, the number of headaches experienced by
patients given placebo increased back to values that were not different than baseline (Fig 14).
Table 10. (Continued)
Drug 1 Drug 2 Study (year) Standardized Mean Difference (95% CI)δ Heterogeneity
Propranolol Metoprolol Olsson (1984) 0.00 (-0.46 to 0.46)
Propranolol Metoprolol Scholz (1987) 0.03 (-0.58 to 0.65)
Propranolol Metoprolol Pooled SMD 0.15 (-0.27 to 0.57) Q = 1.14, df = 1, I2 = 12.6
Propranolol Nadolol Olerud (1986) 0.37 (-0.39 to 1.13)
Propranolol Nadolol Ryan (1984) -0.42 (-1.15 to 0.27)
Propranolol Nadolol Sudilovsky (1987) 0.28 (-0.08 to 0.64)
Propranolol Nadolol Pooled SMD 0.19 (-0.18 to 0.56) Q = 2.81, df = 2, I2 = 28.9%
Propranolol Nifedipine Albers (1989) 0.84 (-0.12 to 1.79)
Propranolol Nifedipine Gerber (1991) -0.63 (-1.30 to 0.05)
Propranolol Nifedipine Scholz (1987) -0.46 (-1.29 to 0.37)
Propranolol Nifedipine Pooled SMD -0.14 (-0.98 to 0.71) Q = 10.41, df = 2, I2 = 61.6%
Propranolol Nimodipine Formisano (1991) -0.19 (-1.10 to 0.73) —
Propranolol Topiramate Ashtari (2008) -0.24 (-0.27 to 0.75)
Propranolol Topiramate Diener (2004) 0.12 (-0.08 to 0.32)
Propranolol Topiramate Pooled SMD -0.02 (-0.30 to 0.33) Q = 1.65, df = 2, I2 = 39.5%
Topiramate Flunarizine Luo (2012) 0.23 (-0.07 to 0.53)
Topiramate Frovatriptan (abortive) Cady (2011) -0.49 (-1.09 to 0.11)
Topiramate Topiramate+Flunarizine Luo (2012) 0.35 (-0.07 to 0.78)
Topiramate Lamotrigine Gupta (2007) -0.30 (-0.83 to 0.22)
Topiramate Topiramate + Nortriptyline Krymchantowski (2012) 0.53 (0.04 to 1.02)
Afshari (2012) -0.32 (-0.85 to 0.20)
Shaygannejad (2006) -0.19 (-0.68 to 0.30)
Topiramate Valproate Pooled SMD -0.28 (-0.70 to 0.15) Q = 0.09, df = 1, I2 = 0.0%
Topiramate Zonisamide Mohammadianinejad (2011) -0.26 (-0.72 to 0.19)
Valproate Cinnarizine Togha (2008) -0.07 (-0.42 to 0.28)
Valproate Flunarizine Mitsikostas (1997) -0.06 (-0.67 to 0.56)
Chronic Migraine (>15 headaches/month)
Amitriptyline Amitriptyline+Fluoxetine Krymchantowski (2002) -0.44 (-1.20 to 0.33)
Pizotifen Naproxen Behan (1986) 0.08 (-0.56 to 0.73)
Propranolol Atenolol Stensrud (1980) 0.08 (-1.40 to 1.56)
Propranolol Nortriptyline Domingues (2009) -0.83 (-0.06 to -1.61)
Topiramate Valproate Bartolini (2005) -0.13 (-0.72 to 0.46)
δ negative number favors drug 1, positive number favors drug 2 in these comparisons.
doi:10.1371/journal.pone.0130733.t010
Meta-Analysis of Prophylactic Treatment of Migraine Headaches
PLOS ONE | DOI:10.1371/journal.pone.0130733 July 14, 2015 45 / 60
Fig 13. Network meta-analysis
doi:10.1371/journal.pone.0130733.g013
Fig 14. Placebo effect of treatment of episodic migraine headaches.
doi:10.1371/journal.pone.0130733.g014
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Side Effects
Patients receiving prophylactic treatment were more likely than those receiving placebo to
experience side effects (RR: 1.27, 95% CI: 1.19 to 1.37) and to withdraw from treatment (RR:
1.18, 95% CI: 1.08–1.29). The specific side effects varied by study medication (Table 11).
Drowsiness was the most common side effect, increased among patients taking gabapentin,
pizotifen, topiramate, TCA and valproate. Tricyclic antidepressants also caused dry mouth and
weight gain. Beta-blockers were associated with feeling depressed, dizzy and insomnia. Topira-
mate increased rates of nausea and paresthesia. Pizotifen had marked increased rates of weight
gain with participants averaging 4.3 kg (95% CI: 3.0–5.6).
Network meta-analysis and direct comparisons found no difference in likelihood of
experiencing “any” side effect or in the rate of withdrawing from studies.
Sensitivity Analysis
There was evidence of publication bias for beta-blockers (Egger p = 0.02), and for each of topir-
amate (p = 0.001) and valproate (p = 0.04). There was no evidence of publication bias for the
remaining drugs or classes. The metatrim test reduced the effect estimate four these four drugs,
though only for valproate did the adjusted effect become insignificant (beta-blocker SMD:
-0.24, 95% CI: -0.45 to -0.04; topiramate: SMD: -0.35, 95% CI: -0.57 to -0.12; valproate: SMD:
-0.40, 95% CI: -0.90 to 0.10).
There were a number of quality problems (Tables 4 and 9). However, total Jadad score
(p = 0.51), intention to treat (p = 0.84), sequence generation (p = 0.47), concealed allocation
(p = 0.18), blinding (p = 0.84) or industry sponsorship (p = 0.17) had no relationship or impact
on pooled outcomes.
The amount of heterogeneity varied considerably among the various drugs and drug classes.
Longer duration of treatment was associated with greater effects for tricyclic antidepressants
Table 11. Side Effects Compared with Placebo.
Alpha
Blockers
Anti-
convulsants
Beta
Blockers
Calcium Channel
Blockers
Flunarizine SSRI TCA
“Any” side
effect
1.25 (0.91–
1.71)
1.20 (1.14–
1.27)
1.65 (1.41–
1.93)
1.25 (1.03–1.53) 1.26 (0.67–2.37) 1.0 (0.51–
1.97)
1.54 (1.37–1.74)
Withdrawal 1.07 (0.65–
1.78)
1.23 (1.13–
1.34)
1.29 (1.03–
1.61)
1.14 (0.84–1.57) 1.0 (0.3–3.2) 1.13 (0.79–
1.61)
1.53 (1.27–1.85)
Depression 3.0 (0.13–
70.6)
ns 4.1 (1.1–15.2) 0.2 (0.01–4.0) 0.7 (0.1–3.4) ns ns
Dizziness 1.80 (0.36–
9.08)
1.61 (1.16–
2.21)
1.75 (1.04–
2.95)
1.19 (0.45–3.18) ns 1.28 (0.23–
7.14)
1.20 (0.77–1.86)
Fatigue 2.65 (0.94–
7.51)
2.22 (1.67–
2.96)
1.19 (0.90–
1.56)
3.07 (1.26–7.48) 1.3 (0.7–2.1) ns 1.84 (1.25–2.71)
Dry Mouth 7.09 (2.31–
21.7)
2.33 (0.43–
12.8)
ns 0.21 (0.01–4.27) 0.26 (0.03–2.3) ns 2.32 (1.63–3.28)
Nausea/
vomiting
1.50 (0.27–
8.3)
1.44 (1.01–
2.03)
1.8 (1.05–
3.02)
0.68 (0.37–1.24) 0.12 (0.01–2.0) (1
study)
2.15 (0.80–
5.8)
1.18 (0.42–3.3)
Parasthesias 6.2 (1.5–26.3) 4.2 (2.7–6.6) 1.4 (0.49–4.2) 5.0 (0.25–101.9) ns ns 1.5 (0.26–9.0) (1
study)
Sleep
disturbance
Ns 0.84 (0.53–
1.33)
1.64 (1.08–
2.5)
Ns ns 1.27 (0.66–
2.5)
0.63 (0.36–1.1)
Weight gain Ns 1.02 (0.12–8.5) 6.1 (0.73–
51.3)
3.08 (0.60–15.9) 0.79 (0.36–1.71) (4
studies)
ns 1.65 (1.02–3.04)
doi:10.1371/journal.pone.0130733.t011
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(β = -0.06, 95% CI: -0.09 to -0.03) as well as for valproate (β = -0.02, 95% CI -0.04 to -0.01) and
flunarizine (β = -0.03, 95% CI -0.07 to -0.001). The other treatment options did not appear to
be time-sensitive. There was no relationship between type of measurement (frequency vs. head-
ache index) and outcomes (p = 0.72). Age, percent women, sample size, dropout rate, percent
of maximum dose attained, study design and whether or not depressed patients were allowed
to participate had no relationship with outcomes.
Discussion
There has long been consensus that some drugs are useful in prophylaxis against migraine
headaches. Our review confirms that there is good evidence for amitriptyline, atenolol, flunari-
zine, fluoxetine, metoprolol, pizotifen, propranolol, timolol, topiramate and valproate in reduc-
ing episodic migraine headache. At baseline, episodic migtaine sufferers averaged slightly over
six headaches per month and most drugs reduced the number of headaches by 1 or 2 per
month. Amitriptyline had the greatest benefit and while the network meta-analysis suggested
that it was the most effective drug for preventing migraine headaches, this was not confirmed
in clinical trials in which amitriptyline was directly compared with other drugs (including
SSRIs, topiramate and propranolol), though all candidate drugs have not been included. Beta-
blockers (atenolol, propranolol, timolol), anticonvulsants (topiramate, valproate), flunarizine
and pizotifen had moderate benefit in reducing headache burden while the serotonin reuptake
inhibitors had a small effect.
On average, across the effective prophylactic medications, migraine sufferers had about twice
the chance of experiencing at least a 50% reduction in headaches as those receiving placebo. Our
pooled risk reduction (ARR: 0.15, 95% CI: 0.09–0.21) suggests that 7 people would need to be
treated to produce 50% reduction in headache burden in one subject. Side effects were common,
but were predictable based on the drug mechanisms of action and are well-known.
There was a significant placebo effect that was seen within 4 weeks of placebo initiation with
a gradual increase in the benefit of placebo on headaches through 12 weeks. By week 16,
patients randomized to placebo had a gradual increase in the number of headaches experienced
with no difference from baseline through 24 weeks of treatment. This is similar to the placebo
effect we saw in our meta-analysis of pediatric migraine trials [233]. Uncontrolled trials of
drugs for treatment of migraine headaches are still published, our data reinforces the impor-
tance of placebo controls.
Our study is the first to pool all the data from the numerous randomized controlled clinical
trials to explore potential differences for both continuous and dichotomous outcomes and for
both episodic and chronic migraine headaches. We also avoid a common error found in previ-
ous meta-analyses in which researchers pooled the outcome at the end of the study, regardless
of the time point. This inappropriately pooled studies of different treatment durations.
There have been no previous systematic reviews of ACE/ARB, flunarizine or beta-blockers
other than propranolol for migraine headaches. A recent Neurology Academy review was lim-
ited by several factors: 1) it included only studies since 2009, 2) it provided only qualitative
statements about the level of evidence with no formal pooling of data and 3) it had no compar-
ative effectiveness data [27]. While our findings are similar to previous reviews of anticonvul-
sants [234], the beta-blocker propranolol [235], anticonvulsants [236] and tricyclic
antidepressants [237], we found some important differences. Anticonvulsants were less effec-
tive than a 2004 Cochrane review[234], though our review includes nearly twice as many stud-
ies. A 2004 Cochrane beta-blocker review included exclusively propranolol, while we include
all beta-blockers. Our 2010 TCA review[237] inappropriately pooled both migraine and ten-
sion headaches together. Our 1996 review [238] also combined migraine and tension
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headaches, likely inappropriate given potentially important pathophysiologic differences. A
2005 Cochrane review of SSRIs found no benefit[239], but that trial was largely based on ten-
sion headaches and it also combined both migraine and tension headaches in their pooled anal-
ysis. In contrast, our larger review focuses on migraine headaches and suggests a modest effect
from fluoxetine. To date, there have been no quantitative systematic reviews comparing the dif-
ferent classes of treatment, though one recent qualitative systematic review concluded that the
choice should be tailored to patients based on side effects and comorbidities [240].
A recent systematic review examined the efficacy of prophylactic treatment for episodic
migraine headaches[28] in reducing headaches by 50%, a dichotomous outcome. Our study
includes both continuous and dichotomous outcomes and examines the effects for both epi-
sodic and migraine headaches. That study was limited to English language only and includes a
smaller number of studies than this analysis. Our results are similar and in agreement with
their conclusion that there is no difference in efficacy between the different drugs; however we
found that the benefit for most drugs was less than they reported.
Our study has a number of important limitations. First the pooled differences between the
various drugs and classes suggested important clinical differences. Some drugs had a large
effect in headache reduction, others only small or modest ones. Our network meta-analysis
suggested superiority for amitriptyline, a finding not confirmed in head-head trials. While
there have been 51 trials directly comparing different drugs, these comparisons have been
somewhat haphazard and many important potential comparisons have not been made.
Conclusions
Our data suggests that the current practice of tailoring prophylactic medication according to
patient characteristics and expected side effects is a good approach. Patients with migraine
headaches and hypertension should consider trials with a beta blocker. Patients with depres-
sion may benefit from either SSRI or TCA. Patients with restless leg syndrome or another indi-
cation for an anticonvulsant may benefit from topiramate or valproate. Our analysis suggests
that amitryptyline is more effective than the other medications, this has not been confirmed in
the limited number of direct comparative effectiveness trials that have been conducted. The
placebo effect, that lasts through at least 12 weeks in our study, suggests that non-placebo con-
trolled trials should not be performed. Nearly all studies of headache treatment were 24 weeks
or less in duration, this is an important limitation since migraine is a chronic condition.
Whether treatment benefit persists, increases or wanes is unknown and deserving of further
studies. The paucity of head-to-head comparative effectiveness trials between some classes of
medication also indicates a direction for future headache research.
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